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ABSTRACT 
 
Chronic kidney disease affects 10-13% of the population. The dominant processes 
that promote kidney disease, irrespective of the trigger, occur in the stromal 
compartment where fibrosis is considered the hallmark of progressive renal disease. 
Recent studies have highlighted the importance of the vasculature and the role of the 
renal pericyte as a progenitor of activated matrix-depositing stromal myofibroblasts, 
cells that drive the development of renal fibrosis.  
 
CD248 is a 175 KDa type I transmembrane glycoprotein expressed at low levels in 
non-inflamed kidney by resident renal stromal cells (pericytes and myofibroblasts).  In 
this thesis I demonstrate that CD248 expression is increased in a cohort of patients 
with progressive renal fibrosis (n=93). Furthermore, increased CD248 expression in 
the kidney stroma is an independent risk factor for the progression of renal disease. I 
have then used an established murine model of renal fibrosis (unilateral ureteric 
obstruction) to characterise the origin, phenotype and function of CD248+ cells in 
vitro and in vivo. A transgenic mouse, with a targeted disruption to the CD248 gene 
has been used to assess the causal role that CD248 plays in the pathogenesis of 
renal fibrosis. Mice deficient in CD248 are protected against myofibroblast 
accumulation, tissue fibrosis and microvascular rarefaction following renal injury. In 
vitro data suggests that this phenotype may be due to a defect seen exclusively in 
stromal cell, but not epithelial cell, function as a consequence of the loss of CD248. 
Taken together these studies suggest that CD248 represents a novel stromal cell 
specific target for the treatment of chronic kidney disease. 
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CHAPTER 1 
BACKGROUND AND LITERATURE REVIEW 
1.1 Introduction 
Globally chronic kidney disease (CKD) affects 1 person in 8 of the population and 
contributes considerably to premature morbidity and mortality (1). Only a small, yet 
significant proportion of patients with CKD will progress to end stage renal failure 
(ESRF) requiring Renal Replacement Therapy (RRT) in the form of dialysis or 
transplantation. It is becoming increasingly recognised that even relatively mild renal 
impairment is a significant independent risk factor for cardiovascular disease and 
stroke (2, 3). Unfortunately current therapeutic options to arrest disease progression 
in patients with moderate to severe renal disease are limited. This has significant 
cost implications and the management of renal disease and its associated 
complications account for nearly 5% of the total National Health Service annual 
expenditure (4). The dominant processes that promote progressive kidney disease, 
irrespective of the trigger, occur in the renal stromal compartment where fibrosis is 
considered the hallmark of progressive disease (5).  
 
This thesis seeks to identify the role of the novel stromal fibroblast and pericyte 
marker CD248 in renal fibrosis. In this chapter the structure and function of the renal 
stroma in health and disease is first discussed and then framed within its clinical 
context.  The cellular and non-cellular mediators in the evolution of fibrosis are then 
described. Finally, the literature detailing our current understanding of CD248 is 
reviewed.  
$"
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1.2 Overview of renal anatomy  
The mechanisms and processes of the human kidney involved in regulating blood 
pressure, clearing toxins and secreting a number of hormones are important to 
health. Humans have 2 kidneys. Each weighs approximately 150 grams and 
measures 12 cm in length (6). The outer most layer of the kidney is transparent and 
is referred to as the capsule. Inside the kidney capsule two further layers are 
recognised. The first of these is referred to as the cortex and the second is known as 
the medulla. Each kidney has approximately 1 million functional units distributed 
through its structure known as nephrons. Individual ephrons consist of a glomerulus 
and a tubule (6). The glomerulus filters toxins and fluid from the blood. The tubules 
modify the filtrate through reabsorption and secretion to form urine. The renal 
microvasculature is organised into two sequential capillary beds (see Figure 1.1) thus 
allowing exquisite balance between glomerular filtration and tubular reabsorption and 
secretion (7). The stroma of the kidney comprises the extravascular inter-tubular 
spaces of the renal parenchyma (8). 
Figure 1.1 
 
Schematic diagram of a nephron and its vasculature  
 
Nephrons consist of a glomerulus and a tubule. The renal microvasculature is organised into two sequential 
capillary beds [adapted from (9) ]. 
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1.3 The renal stroma (interstitium) 
The renal stroma, more commonly referred to as the renal interstitium or 
tubulointerstitial space, makes up 90% of total kidney volume (5). In healthy resting 
tissue the stroma serves two main roles; the provision of structural support, and the 
maintenance of homeostasis in the associated parenchyma (10).  
 
The stroma is derived from the embryonic mesoderm (11) and is situated in the 
space between the basement membrane of the epithelial cells that form the renal 
tubules and the peri-tubular capillaries. The stromal space contains cells, 
extracellular fibrillary structures, proteoglycans, glycoproteins and interstitial fluid (8). 
Stromal fibroblasts within the interstitium provide a framework which helps to 
maintain the three dimensional architecture of the tissue and also produce 
homeostatic regulatory substances such as erythropoietin and adenosine (12, 13). 
The stromal space is also part of the mononuclear phagocytic system with dendritic 
cells forming a tightly enlaced network with stromal renal fibroblasts. Pericytes are 
found in the stromal compartment, located between the cortical efferent arterioles 
and the peri-tubular capillaries, where they are enclosed by a basement membrane 
(12). Otherwise in the normal healthy renal stroma, aside from the occasional 
macrophage, other cell types are rarely seen (8, 12, 13). 
 
Fibrosis is the formation of excess amounts of fibrous connective tissue resulting 
from chronic inflammation of the tissue (5). The extent of tubulointerstitial fibrosis 
seen at kidney biopsy has been repeatedly demonstrated to be a rigorous, reliable 
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predictor of renal disease progression (14). The stroma supports the evolution of 
fibrosis. This occurs directly, by depositing pathological amounts of matrix, 
destabilising the renal vasculature and secreting pro-fibrotic cytokines, and indirectly 
by supporting the survival of infiltrating leucocytes. Consequently, a detailed process 
map of the biological mechanisms of the microenvironment in which inflammation 
takes place is crucial to help understand the pathogenesis of renal fibrosis.  
 
1.4 Glomerular versus tubulointerstitial injury 
The stroma is the stage on which the final act of progressive renal fibrosis is played 
out, but as highlighted by Schlondorff (7), it is also important to consider the 
underlying anatomy of the kidney when considering how injury is initiated. The 
arrangement of the glomerular and peri-tubular vasculature (see section 1.2) and the 
passage of the glomerular ultrafiltrate downstream to the tubules render the kidney 
vulnerable, not only to vascular compromise but also to the spreading of 
inflammation throughout the renal compartment. Glomerular and tubulointerstitial 
injury are therefore considered interdependent. 
 
Damage to a single glomerulus may lead to peri-tubular inflammation and tubular 
atrophy that can progress to loss of the whole nephron (15). Secondary localised 
tubulointerstitial inflammation can equally spread to adjacent tubules and cause 
further damage and nephron loss. Remaining glomeruli develop capillary 
hypertension to maintain function, and as a result secondary glomerulosclerosis 
develops. Damaged glomeruli can also leak pro-inflammatory molecules downstream 
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to the tubulointerstitium (16). Thus regardless of the originating compartment 
(glomerular or tubulointerstitial) chronic inflammation develops and progresses to 
stromal fibrosis through a final common pathway, ultimately producing the single 
indistinguishable pathological renal phenotype of chronic kidney disease. 
Histologically this phenotype is characterised macroscopically by small, scarred, 
shrunken fibrotic kidneys due to the replacement of functioning parenchyma by 
organised contracted matrix. Microscopically there is glomerulosclerosis, vascular 
sclerosis and tubulointerstitial fibrosis (5) 
 
1.5 Chronic kidney disease 
1.5.1 Epidemiology 
CKD, defined as the presence of a marker of kidney damage such as protein or 
blood in the urine or a reduction in kidney function for 3 or more months (17), is a 
major public health problem affecting 10-13% of the population (1). In the Western 
world the major causes of CKD are diabetes mellitus, hypertension and 
glomerulonephritis (18). 
 
The number of patients with CKD is rising and this is mirrored in the increase in 
ESRF requiring RRT globally (4). In the UK the annual incidence of ESRF has 
doubled over the last decade (4). Figures taken from the UK Renal Registry show 
that in 2008 there were 47,525 adult patients receiving RRT equating to a UK 
prevalence of 774 per million population, an annual increase in prevalence of 4.4% 
(19). The UK increase in prevalence, as in other countries, is projected to continue at 
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a rate of 5-8% per year (20). Quantifying the number of patients with ESRF alone 
probably underestimates the population burden of CKD as only a small proportion of 
patients with stage 3 to 4 CKD (see below) progress to RRT (21). Despite this, even 
the early stages of CKD are associated with an increased risk of developing vascular 
and cardiovascular disease (22, 23). Consequently preventing or ameliorating CKD 
and its pathological phenotype of stromal fibrosis is desirable regardless of the 
underlying mechanism of renal injury or disease stage. 
 
1.5.2 Classification of CKD 
In 2002 the Kidney Disease Outcomes Quality Initiative (K/DOQI) published clinical 
practice guidelines to identify and classify patients with kidney disease (17). These 
guidelines use a previously described mathematical formula (24) to calculate an 
estimate of an individual’s renal function from plasma creatinine, age, sex and ethnic 
origin. This is known as the estimated glomerular filtration rate (eGFR). The eGFR is 
widely used to triage patients into distinct stages of renal disease (Table 1.1) 
 
Table 1.1 Chronic kidney disease staging [ Adapted (17) ] 
Stage eGFR  
ml/min/1.73m2 
Description 
1 > 90 Normal kidney function but with the presence of urine abnormalities or a structural/genetic defect. 
2 60-89 Mild renal impairment 
3A 
3B 
45-59 
30-44 Moderate renal impairment 
4 15-29 Severely reduced renal function 
5 
<15 
or 
on dialysis 
Very severe approaching or already established on renal 
replacement therapy 
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Following the publication of these guidelines there has been increasing interest within 
the renal community in screening sections of the population to identify and treat 
patients with CKD who also exhibit additional known clinical determinants of 
progression to ESRF. 
 
1.5.3 Determinants of disease progression 
Multiple predictors of renal progression are now recognised (25). However, 
combining these factors is likely to be more effective when developing scoring 
systems to identify patients at high risk of disease progression (1, 21, 26).    To 
simplify discussion, the most common clinically recognised determinants of disease 
progression are individually discussed below. 
 
1.5.3.1 Proteinuria   
In health, negligible amounts of protein are found in the urine as large molecular 
weight proteins are not filtered through the intact glomerular basement membrane; 
any low molecular weight proteins that are filtered are reabsorbed by the renal 
tubules.  In disease states these mechanisms are impaired and clinically urinary 
protein loss can be measured using either the protein creatinine ratio (PCR) or the 
albumin creatinine ratio (ACR). In adults it is preferable to measure the urinary ACR, 
as this is a more sensitive marker, than total urine protein loss (PCR), for chronic 
kidney disease (17). Individuals who have renal disease and an ACR greater than 
100 mg/mmol are known to be at significantly higher risk of progressing to ESRF (1). 
Population based studies have previously demonstrated proteinuria to be a predictor 
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of future decline in renal function and the development of ESRF (27, 28). In addition 
to being a determinant of renal progression, proteinuria is also a target for treatment 
as urinary protein loss drives cytokine release, damage to tubulointerstitial cells and 
localised fibrosis (29).The blockade of the renin angiotensin system has been 
demonstrated to reduce proteinuria and improve outcome in multiple clinical cohorts 
(30). 
 
In our group we have previously demonstrated a close association between 
albuminuria, urinary cytokines (MCP-1/CCL2), and interstitial macrophage infiltration 
with in situ renal fibrosis and clinical outcomes (31, 32). These studies also 
demonstrated that although proteinuria is important in early disease as renal scarring 
evolves, alternative pathways relating to progressive tissue ischemia secondary to 
microvascular rarefication (see below) might be more important. The clinical 
importance of proteinuria is emphasised by the modification of the K/DOQI clinical 
practice guidelines to include the suffix ‘P’ to denote significant proteinuria (33, 34) 
 
1.5.3.2 Hypertension 
Systemic hypertension, which can be both a cause and a consequence of renal 
disease, leads to intraglomerular hypertension with subsequent hypertrophy and 
damage. Hypertensive patients when compared to normotensive patients with CKD 
progress to ESRF faster (35-37). 
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1.5.3.3 Estimated glomerular filtration rate (eGFR) 
A reduction in eGFR is not only a marker of CKD, it is a determinant of renal 
progression (1, 38) and reflects functioning nephron mass at the time of diagnosis. 
Tsuboi et al have shown in a wide range of glomerulonephropathies that assessing 
glomerular density in renal biopsy sections, as a proxy measure of functional 
nephron mass, is a useful tool to help determine disease outcome (39-41).  Although 
eGFR is strongly associated with progressive disease it is now recognised that all 
levels of reduced eGFR should be complemented by quantification of proteinuria to 
optimally predict progression to ESRF(1). 
 
1.5.3.4 Histology 
To investigate the underlying aetiology of a patient’s renal disease, a renal biopsy is 
often performed. This involves removing a small sample of kidney using a needle 
under local anaesthetic. Renal biopsy samples can also be used to assess the 
degree of stromal fibrosis at presentation and this can then be used to predict renal 
progression. Multiple methodologies exist within the literature for this purpose but 
broadly two main features are examined either individually or in combination: 
 
1. Chronic damage. Bohle et al (14) first described the negative correlation 
between the amount of stromal damage seen in biopsy samples and renal 
function and prognosis. These observations have subsequently been validated 
in a diverse range of renal pathologies and also in a number of animal models. 
Stromal damage can be quantified either using a simple grading system or 
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more objectively, measured using digital image analysis software. Our group 
have previously refined this approach and described the Index of Chronic 
Damage, an established and rigorous morphometric measure that predicts 
renal outcome (42). 
 
2. Capillary rarefaction. Chronic hypoxia plays a role in the evolution of renal 
fibrosis (43). Progressive CKD is associated with capillary rarefaction and a 
reduced blood flow within those that remain (32, 44). Studies by our group and 
others to quantify capillary density have shown a link between a reduction in 
capillary density and a worse disease outcome (32). This approach is 
predominantly used as a research tool at present. 
 
1.6 IgA nephropathy as a paradigm of progressive renal fibrosis 
This thesis uses the human kidney disease IgA nephropathy as a model of 
progressive renal injury. Previously thought to be a relatively benign condition, it is 
now recognised that approximately 30-50% of patients with IgA nephropathy will 
progress to ESRF requiring RRT after 20 years (45). 
 
First described by Berger in 1968, IgA nephropathy is the most commonly occurring 
cause of primary glomerulonephritis and is an excellent example of progressive renal 
disease (46). IgA nephropathy is thought to be caused by the deposition of 
abnormally glycosylated IgA within the glomerulus leading to mesangial expansion 
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and loss of glomerular structural integrity (Figure 1.2). Glomerular damage leads to 
tubulointerstitial inflammation and the loss of functional renal parenchyma. 
 
Figure 1.2 
Histological features of IgA nephropathy 
(A) A normal glomerulus. (B) PAS staining. A glomerulus from a patient with IgA nephropathy showing mesangial 
expansion. (C) Immunofluorescence microscopy. IgA deposition (bright green) can clearly be seen within the 
diseased glomerulus. [ Adapted from (47) ] 
 
IgA nephropathy is more common in men than women (2:1 ratio) and although the 
disease can be diagnosed at any age it normally presents between the ages of 20 
and 40 (46). There is a strong geographical variation in the prevalence of IgA 
nephropathy. It is more common in Asia where it is found in approximately 40% of all 
biopsy specimens collected for the investigation of suspected glomerular disease. 
Whilst genetic differences may account for this increased prevalence there is also an 
element of reporting bias (47). There are a number of school screening programs in 
Asia designed to detect early urine abnormalities suggestive of IgA nephropathy, 
furthermore the threshold to proceed to renal biopsy is lower in Asia than in the UK. 
 
Regardless of the country of diagnosis, patients are assessed using the clinical and 
histological predictors of disease progression described above. Thus those patients 
with poor renal function, elevated blood pressure, persistent proteinuria (ACR >100 
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mg/mmol) and evidence of tubulointerstitial fibrosis at first renal biopsy are more 
likely to reach ESRF over time. 
 
1.7 Pathogenesis of progressive renal fibrosis 
It is perhaps simplest to consider renal fibrosis as a form of wound healing (48). 
Renal fibrosis most likely begins as a beneficial response to acute injury. Commonly 
recognised mechanisms of renal injury are summarised in Table 1.2.  
 
Regardless of the underlying mechanism of injury, the ultimate aim of wound healing 
is restoration of tissue architecture and function and the renal response to injury 
resembles that seen elsewhere in the body (49). Following injury, neutrophils infiltrate 
wounded tissue and epithelial cells proliferate (48). As the healing process evolves, 
neutrophils are replaced by macrophages and T cells that are supported by resident 
stromal fibroblasts and dendritic cells (5, 49). Fibroblasts and pericytes proliferate 
and become myofibroblasts that deposit pathological amounts of matrix and facilitate 
wound contraction and scar formation (fibrosis) (50, 51). Intriguingly, in the foetus 
complete tissue regeneration is possible (52). Unfortunately in the post-embryonic 
state repair involves inflammation (7). In adult tissue, healing is often only partially 
successful and acute inflammation may evolve into persistent chronic fibrosis 
associated with the deposition of excessive extracellular matrix (ECM). Consequently 
the mechanisms of inflammation and fibrosis are interrelated and dysregulation of 
this process leads to an inappropriate pro-fibrotic response and chronic inflammation 
(5).  
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Table 1.2 
  
Mechanisms of renal injury  
 
 
Cause Example 
Inflammatory process 
 
Infection 
Primary interstitial nephritis 
Secondary glomerulonephriitis 
Trauma 
Vascular 
Obstruction 
Radiation 
Drugs Analgesic nephropathy 
Metabolic Diabetes 
Hereditary Polycystic kidney disease Alport’s syndrome 
[Adapted from (53)] 
The discussion that follows describes the main cellular and non-cellular mediators of 
renal fibrosis. Attention is focused predominantly on the interstitium but it is important 
to remember that, as discussed above, the glomeruli are also involved in the initiation 
of renal fibrosis. To simplify discussion, individual mediators are described in 
isolation and greater emphasis has been placed on the role stromal cells play in this 
process. Ultimately however, renal fibrosis is a complex interplay between all the 
factors described. 
 
1.7.1 Cellular mediators 
1.7.1.1 Macrophages 
The non-inflamed kidney has relatively few tissue macrophages (13). Infiltration of 
renal tissue by monocyte/macrophages following injury is described in both human 
disease and animal experimental models (31, 32, 54). In human disease, 
macrophage infiltration is negatively correlated with renal outcome (31) and fibrosis 
can be ameliorated in animal models following the systemic depletion of 
macrophages (55-57). Recruitment of circulating monocytes to the injured kidney is 
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in response to the upregulation and de novo expression of selectins and integrins by 
endothelial cells of the post-capillary venules, and by chemokine release from the 
kidney itself.  These factors orchestrate rolling, adhesion and transmigration of 
activated monocytes into the kidney where they are involved in tissue repair; 
sterilising and debriding injured tissue through the release of cytotoxic substances 
and phagocytosis (58). 
 
Repetitive injury or chronic inflammation drives aberrant macrophage activation that 
initiates fibrosis. This occurs through the dysregulated release of reactive oxygen 
species (ROS) that are directly damaging to tissue and also through the generation 
of pro-fibrotic cytokines such as TGFβ, FGF and PDGF that promote leukocyte 
recruitment and ECM deposition by stromal cells (29). Macrophages can also directly 
remodel renal architecture through the release of metalloproteinases (see below) 
(59). 
 
In vivo macrophages are a heterogeneous population of cells that can be divided into 
two polarised activation states (60). The classically activated, also referred to as the 
M1 macrophage can be induced by exposure to IFNγ, lipopolysaccharide, TNFα or 
GM-CSF. The M1 macrophages express pro-inflammatory cytokines such as IL-6, IL-
1β, TGFβ, PDGF and reactive oxygen species (ROS). Exposure to IL-4 or IL-13 leads 
to alternatively activated or M2 macrophages, that are thought to promote tissue 
repair (61). Evidence is mounting that early in the development of injury 
macrophages adopt an M1 phenotype but at later stages of disease an M2 
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phenotype predominates. Depletion studies performed in murine models of both liver 
and kidney fibrosis have demonstrated that macrophage depletion in the context of 
advanced fibrosis resulted in reduced tissue scarring. In contrast depletion during the 
recovery phase of injury led to a failure of matrix removal (61, 62). 
 
1.7.1.2 T cells 
T cells are rarely found in non-inflamed renal tissue (13) and until relatively recently 
the idea that T cells play a direct role in the pathogenesis of renal fibrosis has 
received scant attention. Renal immune-mediated T cell injury is well described 
within the literature (63). It has long been assumed that T cells generate injury to 
which fibrosis is the response. An argument supported by early reports suggesting T 
cells do not directly contribute to the development of renal fibrosis (64).  There is now 
mounting evidence that T cells directly promote renal fibrosis.  
 
Kalluri et al used a murine model of Alport’s renal disease to demonstrate that T cells 
are not required for the induction of glomerulonephritis, but they are required for the 
development of interstitial fibrosis (65). Similarly, Niedermeier et al induced renal 
fibrosis in severe combined immunodeficient (SCID) mice that lack T and B-
lymphocytes; demonstrating a substantial reduction in collagen deposition in SCID 
mice kidneys compared to controls following injury. This phenotype could be 
replicated in wildtype animals by the administration of an anti-CD4 antibody following 
disease induction (66). 
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More recently this approach has been replicated and refined by the adoptive transfer 
of either CD8+ or CD4+ T cells into Rag-/- mice following injury (67).  CD4+ but not 
CD8+ T cells were found to increase fibrogenesis in this study. The exact mechanism 
for this effect is unclear, however, three possibilities have been suggested (68): 
1. T cells may act directly on resident renal stromal cells to become activated 
and deposit pathological fibrotic matrix; 
 
2. T cell-macrophage crosstalk might induce an M1 macrophage phenotype that 
again activates stromal cells; or, 
 
3. Alternatively, T cells may act on tubular epithelial cells to induce the secretion 
of cytokines and growth factors that subsequently induce indirect stromal cell 
activation. 
 
1.7.1.3 Dendritic cells 
Dendritic cells (DC) are found throughout the renal stroma where they have a role in 
immune surveillance and antigen presentation (69). Murine proteinuric renal disease 
models have demonstrated that albumin fragments filtered at the glomerulus can be 
taken up by proximal tubular cells and presented in draining lymph nodes by renal 
DCs thus priming CD8+ T cells (70). Furthermore, Heyman et al have demonstrated 
that DCs are intimately involved in the progression of proteinuric renal disease (71, 
72); and that DC depletion in a murine model of glomerular injury leads to the rapid 
resolution of immune cell infiltration and damage. Together these studies provide 
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further evidence linking the glomerular and tubular compartments in the 
pathogenesis of renal injury and subsequent fibrosis; and help to explain the clinical 
observation of the detrimental effect of proteinuria on renal disease progression. 
 
1.7.1.4 Mast cells 
An increased number of mast cells is a consistent feature of renal fibrosis, whatever 
the underlying pathology (73-76); these cells have also been implicated in the 
pathogenesis of chronic inflammation in non-renal organs (77). Mast cells increase in 
number in areas of scarring of the renal cortex and have been shown to inversely 
correlate with renal function (78). Animal studies on the role of mast cells in the 
development of renal fibrosis have proved inconclusive. Data from models of renal 
disease, performed in mice deficient in mast cells suggests that fibrosis is worse 
following injury when compared to control animals (79-81). In contrast other 
investigators report a protective effect of mast cell deficiency against the 
development of fibrosis (82). The functional mechanisms by which mast cells 
mediate fibrosis remain unclear. 
 
1.7.1.5 Renal tubular epithelial cells 
Renal tubular epithelial cells (TEC) act as a conduit between the glomerular and 
interstitial compartments (see section 1.4) and thus play a key role in the 
pathogenesis of renal fibrosis. TEC can be damaged directly, for example through 
toxic or ischemic mechanisms (83), and indirectly by glomerular proteinuria or 
cytokine and ROS release from leucocytes (29, 31). In vitro TEC express leucocyte-
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directed chemokines and cytokines in response to high concentrations of 
intermediate weight proteinuria, for example albumin (84). Interventions that 
decrease proteinuria in human clinical trials (29) are protective and, in animal models 
of disease, are associated with reduced chemokine expression and inflammation 
(29). Proteinuria has also been demonstrated to activate complement within the 
tubular lumen (85). A mechanism that could block some or all of the process outlined 
above may therefore be protective against fibrosis (86) 
 
TEC injury is reported to lead to cell cycle growth arrest (87), autophagy  (88, 89) and 
apoptosis (90). These processes culminate in tubular atrophy, loss of functional 
parenchyma and fibrosis. Perhaps more controversially it has been proposed that 
TEC, through the process of epithelial mesenchymal transformation (EMT), directly 
contribute to the activated stromal cell populations of the fibrotic kidney (91-93). 
Evidence for this process in the pathogenesis of renal fibrosis will be discussed in 
more detail later. 
 
1.7.1.6 Endothelial cells, the microvasculature and hypoxia. 
Endothelial cell damage and microvascular rarefaction are seen in pathological 
studies of human renal disease (32, 94) and in numerous animal models (95-97) of 
renal fibrosis. Cell damage and failure of repair mechanisms compromise renal 
perfusion and drive tubular atrophy (98).  Both acute ischemia and inflammation 
activate endothelial cells and causes leucostasis, that in turn compromises blood flow 
(98); injury also induces endothelial cell apoptosis with subsequent failure of capillary 
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repair (99). Defective angiogenesis seen in animal models of renal fibrosis has been 
suggested to be due to an imbalance of pro and anti-angiogenic stimuli (100-102). 
Intuitively the loss of the microvasculature suggests the generation of a hypoxic 
microenvironment and a ‘chronic hypoxia hypothesis’ (103) has been suggested as 
an underlying mechanism of renal fibrosis. 
 
Intra-renal fibrosis itself can exacerbate hypoxia by impairing the efficiency of oxygen 
diffusion (104). Hypoxia directly recruits inflammatory leucocytes (105), stimulates 
pro-inflammatory and angiogenic (106) cytokine release from TEC and drives matrix 
deposition by stromal fibroblasts (107). Destabilisation of the microvasculature in 
response to injury (51, 95) and endothelial mesenchymal transition (108) has also 
been considered to potentially play a role in microvascular rarefaction and ECM 
deposition. 
 
Hypoxia-inducible transcription factors (HIFs) are intricately involved in the kidney’s 
adaptive response to hypoxia (109). HIF is a transcription factor that is degraded 
under normoxic conditions by von Hippel-Lindau (VHL) disease tumour suppressor 
protein. In hypoxic tissue HIF escapes degradation and can activate genes with 
hypoxia response elements in their promoter region (109).  HIFs consist of alpha and 
beta subunits that form heterodimers on activation. Murine models of renal fibrosis 
have shown that HIFs are upregulated in the kidney in response to chronic injury 
(110, 111). The ablation of HIF1α in mice has been shown to be protective against 
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the development of fibrosis (111). In contrast, in the acute setting HIFs have been 
demonstrated to be protective against ischemic renal injury (112). 
 
1.7.1.7 Stromal fibroblasts  
Stromal fibroblasts at renal and non-renal sites are a heterogeneous and functionally 
diverse cell population (50). Fibroblast heterogeneity was first recognised in the 
1960s when Castor et al examined the proliferation rates of fibroblasts derived from 
the dermis, articular cartilage, mesothelial surface and the periostium of bone. 
Mesothelial surface-derived fibroblasts had a slower proliferation rate and deposited 
a greater amount of ECM than fibroblasts derived from other sites (113). More 
recently fibroblasts have been shown to exhibit topographic differentiation, displaying 
distinct functional identities based on their tissue of origin. Chang et al used genome 
wide mRNA microarray analysis to demonstrate distinct differences in fibroblasts 
derived from a variety of human tissue sites (114, 115).  This positional memory and 
topographical differentiation persists during in vitro culture.  In addition to site-specific 
differences, fibroblasts are also heterogeneous within individual tissues. In the lung 
the surface marker Thy-1 has been used to investigate fibroblast subpopulations.  
Thy-1+ and Thy-1- fibroblasts demonstrate morphologically discrete phenotypes 
(116). Further, Thy-1+ fibroblasts produced 3-fold more collagen and less fibronectin 
than Thy-1- cells (117). 
 
In the kidney resident stromal fibroblast heterogeneity has not been addressed in 
detail although subpopulations have been reported (108, 118). In normal human 
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kidney, ‘quiescent’ stromal fibroblasts represent a small population with a low 
turnover rate (119) that play a homeostatic role maintaining and regulating the 
deposition and organisation of ECM.  Ultrastructurally, renal fibroblasts display a 
spindle-shaped appearance with elongated, branching processes. Sub-cellularly they 
have a rough endoplasmic reticulum, a large nuclei and an extensive golgi apparatus 
(119). Fibroblasts have multiple functions beyond simply maintaining normal tissue 
architecture. They play an important role in local and systemic adaptive physiology, 
modulating intrarenal blood flow through their conversion of 5’-AMP to adenosine and 
also in erythropoiesis through the secretion of erythropoietin(13).  Fibroblasts can 
also secrete prostaglandins and cytokines in a paracrine manner (119).  Zeisberg et 
al have also demonstrated that they have endocytic and antigen-presenting capacity 
(120).   
 
1.7.1.7.1 Activated stromal fibroblasts (myofibroblasts) 
The transformation from a quiescent to an activated population of fibroblasts is 
dependent on a combination of growth factors, cytokines, ECM and environmental 
stimuli.  Aside from the activated form of the fibroblast, known as a myofibroblast, 
there are no formal nomenclatures or markers to classify fibroblast heterogeneity. 
The myofibroblast is therefore the prototypical activated stromal fibroblast described 
within the renal literature.  
 
In contrast to fibroblasts, myofibroblasts are larger, exhibit long processes with 
bundles of microfilaments which stain positive for alpha smooth muscle actin (αSMA) 
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(119). αSMA is therefore classically used to define myofibroblasts in vitro and in vivo 
(50), although αSMA- fibroblasts are described in the renal literature and are known 
to contain and express interstitial collagens in vivo (118).  
 
αSMA is a contractile protein that is expressed intracellularly in the cytoplasm of 
activated fibroblasts and is also found extensively throughout the vasculature (121). 
Whilst αSMA has been widely used as a myofibroblast marker, the actual functional 
role of αSMA is less clearly defined. The enhanced expression of αSMA occurs 
rapidly in response to renal injury. Garin et al demonstrated the upregulated 
expression of αSMA in rat mesangial cells after only 45 minutes of renal ischemia 
(122). Increased expression of  αSMA is also seen in organs other than the kidney in 
response to injury (49). In vitro, αSMA molecules incorporated into actin filaments 
function to produce the contraction of collagen gels (123) and also limit cell migration 
and motility by increasing cell adherence to extracellular matrix (124). Intriguingly 
experimentally-induced tubulointerstitial fibrosis in the αSMA-/- mouse showed that 
αSMA-/- animals developed more severe fibrosis compared to controls and that 
fibroblasts isolated from αSMA-null mice produced more type collagen 1 compared to 
wildtype controls in vitro (125). This led the authors to conclude that rather than being 
pro-fibrotic, αSMA may actually suppress and control myofibroblast activity. 
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1.7.1.7.2 Origin of activated stromal fibroblasts in the kidney. 
The origin of activated stromal renal fibroblasts is both controversial and complex. 
Recruitment has been proposed to occur either from resident stromal cell populations 
(peri-tubular fibroblasts and pericytes) or from circulating bone marrow derived 
precursors (fibrocytes) and through the process of EMT (5). EMT is the process 
whereby epithelial cells lose their epithelial characteristics and acquire properties 
typical of mesenchymal cells, thus allowing migration through the extracellular matrix. 
It is a process normally observed in the developing embryo, and within the matrix of 
malignant tumours but has also been reported to occur in fibrotic tissue at non-renal 
sites (e.g lung and liver). More recently endothelial mesenchymal transformation 
(EndMT) has also been suggested as a source of activated stromal fibroblasts at 
least in animal models of CKD (108). Iwano et al attempted to quantitate the relative 
importance of the various potential sources of activated fibroblasts. Using bone 
marrow chimeras and transgenic reporter mice, the authors suggested that resident 
fibroblasts, EMT and circulating precursors contribute 52%, 38% and 9%, 
respectively(126). EndMT and pericytes were not looked at in this study. 
 
Multiple stromal markers have been used to try to identify and distinguish between 
fibroblasts and activated fibroblasts in vivo and in vitro. Furthermore, these markers 
whilst imperfect are often also used to try and classify cell origin and fate. The 
principal fibroblast and activated fibroblast markers described in the literature are 
summarised in Table 1.3. It should be noted that genetic labelling techniques in mice 
that permit reliable fate tracing of cell populations in vivo, are helping to address 
many of the problems previously associated with stromal fibroblast markers (127). 
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The concept that activated stromal fibroblasts are derived from resident renal 
fibroblasts is intuitive, widely accepted by most authors and long-standing. Other 
potential sources such as EMT and circulating fibrocytes are contentious and will be 
discussed here. The evidence that activated stromal cells are derived from resident 
peri-tubular pericytes will be discussed later (section 1.7.1.10) and framed within our 
current understanding of the biology of this under recognised cell. 
 
Table 1.3  
Renal stromal and activated stromal cell markers 
 
Cell type Proposed markers Comment 
Resident stromal 
fibroblasts 
CD73, FSP1, CD90, 
ICAM 
Differentiation between medullary and cortical 
fibroblasts can be made by morphology and 
position. 
Myofibroblasts αSMA αSMA is also expressed by the vasculature of the kidney 
EMT derived fibroblasts FSP1 FSP1 is also expressed by some leucocyte populations 
Pericytes 
αSMA, PDGFRβ, 
CD73, NG2, Desmin, 
CD248 
Marker expression is highly dependent on 
developmental stage and activation status. 
Fibrocytes 
 CD34, Collagen I 
Represent a small population of cells in most 
models of renal fibrosis. 
[Adapted from (50) ]"
 
Fibrocytes, first reported in 1994, are a circulating CD34+ bone marrow-derived, 
monocyte-like, population of fibroblasts (128). These cells constitute less than 1% of 
circulating leucocytes and are defined by their co-expression of both leucocyte and of 
mesenchymal cell markers such as collagen I (129). Fibrocytes are proposed to 
infiltrate inflamed and fibrotic tissue and become activated stromal cells (130). In 
kidney fibrosis infiltrating fibrocytes probably represent a small population of cells 
(126, 127, 130). More recent studies have called the presence of fibrocytes in fibrotic 
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kidney into question (51, 131). Nevertheless these animal models should be 
tempered by the observation of fibrocytes in human disease states (132). 
 
For the last 15 years the predominant theory for the origin of activated stromal 
fibroblast populations, aside from recruitment of resident stromal cells, has been 
through the process of EMT (50). This concept is well established in the cancer 
literature.  Evidence for EMT occurring in the kidney is based on pioneering work by 
Strutz and colleagues (133, 134) who first suggested that tubular epithelial cells can 
de-differentiate to express fibroblast markers in various renal disease states (91, 
135-137) raising the possibility that EMT is a potent source for myofibroblasts in 
CKD.  
 
The fibroblast marker predominately associated with EMT is fibroblast specific 
protein-1 (FSP-1). Although it should be highlighted that this marker is also 
expressed on some leucocyte populations (138). Using in vitro studies and in vivo 
animal models, TEC are reported to acquire a myofibroblast phenotype and express 
FSP-1, a process driven by TGFβ (139). In an ex vivo study in human IgA 
nephropathy with preserved kidney function, there was a negative correlation 
between FSP-1 and renal survival (140). However these observations are 
confounded by FSP-1 expression on infiltrating leucocytes which by themselves are 
known determinants of progressive CKD (31).  Further, despite the extensive 
literature on EMT in the kidney as noted by Kriz et al, there is no experimental 
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evidence to demonstrate that in vivo tubular derived cells are capable of depositing 
type I collagen or that they can migrate across the tubular basement membrane (92). 
 
1.7.1.8 Pericytes 
Pericytes have been relatively neglected in the renal literature in the last 30 years, 
with few publications focusing on their structure, function and involvement in renal 
pathology. More recently, however, there has been an increasing interest in the role 
that pericytes play in the development of renal disease (51, 95, 127, 141-143). They 
are emerging not only as a major contributor to the activated, matrix-depositing, 
stromal cell populations seen in progressive fibrosis, but also, perhaps even more 
importantly, detachment of renal pericytes from the vasculature may drive the 
microvasculature rarefaction and subsequent hypoxia associated with CKD (94, 144). 
Intriguingly, at renal and non-renal sites, the microenvironment in which pericytes 
reside has been suggested to represent a mesenchymal stem cell niche (145).  
 
First described by Rouget as early as 1873 (146) the pericyte is suggested by some 
authors to represent the precursor of vascular smooth muscle cells (VSMC) that are 
seen in larger vessels with which they share some structural and functional 
similarities (147, 148). However, while VSMC lie largely outside the basement 
membrane of endothelial cells, pericytes lie in close proximity to the microvasculature 
(149). 
In vivo, pericytes can be recognised by their extensive, branched processes that 
partially surround the abluminal side of endothelial cells (148, 150). They are 
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ubiquitously found throughout the microvasculature and are sheathed within a 
duplication of the underlying vessel basement membrane. Pericyte density is highly 
variable across vascular beds. Coverage of the abluminal surface of endothelial cells 
is reported to range between 10-50% (151) and the ratio of pericytes to endothelial 
cells is 1:1, 1:2.5 and 1:100 for the retina, kidney and skeletal muscle, respectively 
(143, 151, 152). 
 
Figure 1.3 
Pericyte structure  
Pericytes (PC) surround the abluminal side of endothelial cells (EC) and are sheathed in capillary basement 
membrane (CBM). Gaps in the basement membrane permit intercellular crosstalk between pericytes and the 
underlying endothelial cells through peg and socket processes. [Taken from (141)] 
 
 
Whilst pericyte processes are always enclosed within the basement membrane, the 
cell body is often exposed by gaps in the basement membrane thus allowing 
intercellular crosstalk between pericytes and the underlying endothelial cells (141). 
Pericyte-endothelial crosstalk is facilitated at these sites through peg-socket contacts 
(Figure 1.3) (151). These represent membrane invaginations extending either from 
the pericyte or from the endothelial cell that permit the formation of tight, gap and 
adherence junctions (151, 153). Through these connections an individual pericyte is 
capable of linking to multiple endothelial cells, facilitating co-ordination and 
integration of the underlying endothelium (151). 
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Renal pericytes were first visualised using transmission electron microscopy (TEM) 
and described in detail by Courtoy and Boyle in 1983; their initial structural 
observations suggested a functional role for pericytes in modulating vessel diameter. 
In the kidney, pericytes are found in the tubulointerstitial space on peri-tubular 
capillaries and as specialised pericytes within the glomerulus as mesangial cells 
(141, 143, 154). 
 
1.7.1.8.1 Identifying pericytes in vivo 
Identifying pericytes in vivo is challenging and classical approaches utilising location, 
morphology and surface markers has presented problems. Pericytes appear 
morphologically distinct across different organs (150). As noted by Armulik et al in the 
central nervous system, pericytes appear flattened with multiple cytoplasmic 
processes covering an extensive amount of the endothelial abluminal surface (151). 
In contrast, pericytes within the glomerulus are compact with minimal abluminal 
coverage. In view of these problems, TEM has remained one of the best techniques 
to identify and phenotype pericytes in mature tissues (155). TEM is more difficult 
during angiogenesis and vascular remodelling as the basement membrane is often 
not fully developed (156). 
 
While no pan-pericyte markers exist, surface markers for pericytes are recognised 
although none are entirely specific (Table 1.4). Current markers suffer from 
limitations as they are dynamically expressed at different developmental stages (51), 
across species (151), in different organs (150) and in response to the 
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microenvironment (51, 157). Four of the best described markers used to identify 
pericytes are: αSMA; desmin; NG2 chondroitin sulphate proteoglycan and PDGFRβ. 
All of these pericyte markers are temporally and developmentally expressed by 
pericytes, a phenomenon reported at renal (51, 158) and non-renal sites (151, 159).  
In the kidney, Lin et al have reported that at postnatal day 12, NG2, αSMA and 
PDGFRβ are expressed by all pericytes, but as the organ matures expression of 
these markers is lost as pericytes become less active (51). 
 
Consequently, one approach to identifying pericytes in vivo is to combine multiple 
surface markers (160). The development in recent years of transgenic mice 
(reviewed in detail by Duffield et al (127)) has taken this approach a step further. 
Transgenic animals allow genetic fate tracking and tagging of pericytes thus 
facilitating not only the in vivo localisation of pericytes, but their ex vivo isolation (51) 
and phenotyping. Isolated cells can also be used for in vitro co-culture models (161).  
 
 
 
 
 
 
 
 
31"
"
Table 1.4 
Pericyte markers 
Note the overlap between pericyte and fibroblast markers (Table 1.3) 
Marker Comments 
CD73 Pericyte and mesenchymal stem cell marker (150). 
 
Expression is regulated by tissue hypoxia (162). 
 
Expression also seen on erythropoietin producing peritubular 
fibroblasts of the kidney (150). 
CD248 (TEM1, Endosialin) Recognises pericytes and fibroblasts(163). 
 
Temporal expression with high levels in development and low levels in 
adult tissue (158, 164, 165). 
 
Implicated in PDGFRβ mediated pericyte proliferation in vitro (166, 
167). 
 
Potential therapeutic target. 
Alpha smooth muscle actin 
(αSMA) 
Intracellular marker widely described in pericytes(150, 159). 
 
Restricted to expression by activated pericytes at sites of vascular 
remodelling (168). 
 
Also expressed by smooth muscle cells and myofibroblasts (50). 
Desmin Intracellular marker expressed on intermediate filament proteins 
(150). Can be used as an ensheathment marker to estimate vessel 
stability (169). 
 
Expressed on pericytes in direct contact with the underlying 
endothelium (161, 170). Proposed as an indicator of pericyte 
ensheathment in underlying basement membrane (168). 
 
Expressed by pericytes (mesangial cells) of the glomerulus (171). 
NG2 chondroitin sulphate 
proteoglycan  
(NG2) 
A transmembrane proteoglycan expressed on pericytes but also 
widely expressed on glial cells of the central nervous system (159). 
 
Expressed by nascent pericytes during the early stages of 
angiogenesis and perists in newly formed blood vessels (168). 
Platlet derived growth factor 
beta receptor (PDGFRβ) 
One of the most widely used pericyte markers. 
 
Plays a key role in pericyte recruitment, investment and maturation of 
the microvasculature (150, 161, 170). 
 
Cellular expression persists following pericyte-myofibroblast transition 
(51). 
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1.7.1.8.2 Pericyte function in vessel development 
Pericytes are pivotal to vascular development and remodelling (172, 173). Central to 
vasculogenesis and angiogenesis is the process of vessel maturation i.e. the 
transition from a growing vascular bed to a fully formed, stabilised vascular network. 
A prominent feature of maturation is the investment of pericytes in the vessel wall. 
Defective maturation is seen in pathological settings including malignancy and 
fibrosis (168, 174). 
 
Blood vessels are one of the first embryonic organs to develop and they are 
composed of endothelial cells and mural cells (VSMC or pericytes). During 
development both of these cell populations are derived from the embryonic 
mesoderm. The nascent vasculature is formed through the process of 
vasculogenesis. In the embryo, a rudimentary endothelial tube network is formed 
from endothelial progenitor cells (172). This network is then branched, pruned and 
stabilised through the process of angiogenesis and mural pericytes are thereby 
embedded into the vascular wall (160). Pericytes are important for vessel stability. Ex 
vivo co-culture studies using a 3D gel matrix have demonstrated that the removal of 
pericytes leads to loss of microvascular integrity (175).  In vivo pericyte coverage of 
endothelial cells is essential for maintenance of the blood brain barrier (159). This is 
an observation mirrored by similar reports across multiple vascular beds emphasising 
the role pericytes play in stabilising blood vessels (153). 
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Despite its importance in development, our understanding of the process whereby 
the vasculature is stabilised is incomplete. Generation of a functioning vascular 
basement membrane and recruitment and investment of pericytes into the immature 
vascular network occurs in response to secreted growth factors (160).  Numerous 
growth factors are recognised, but two main signalling systems appear crucial, these 
being the PDGFRβ/PDGF-BB and the angiopoietin-Tie2 signalling pathways (160).  
VEGF, a key signalling molecule produced by endothelial cells to stimulate 
angiogenesis, is involved in both of these pathways. 
 
PDGF-BB is secreted by endothelial cells in response to vascular endothelial growth 
factor (VEGF) stimulation and is crucial for the recruitment of pericytes to newly 
formed vessels (176). Studies in mice demonstrate that loss of PDGFRβ, or its ligand 
PDGF-BB (secreted from endothelial cells), results in defective pericyte recruitment 
and investment in the microvasculature with subsequent vascular leakage and 
haemorrhage (176-178). Once pericyte recruitment to the endothelium is achieved, 
endothelial-pericyte crosstalk and anchoring involves angiopoietin-Tie2 signalling 
pathways. Angiopoietin (Ang) 1 and 2 both signal through the Tie2 receptor (179) but 
have  different functional roles. Ang 1 is expressed by pericytes and is involved in 
reducing vessel permeability through strengthening endothelial-pericyte interactions 
(172). Ang 2 is produced and stored by endothelial cells, antagonises the effects of 
Ang 1 and is involved in the inflammatory response (150). 
 
 
34"
"
1.7.1.8.3 Mesangial pericytes 
Pericytes are found within the glomerular and tubulointerstitial compartments of the 
kidney. There is an extensive literature on the functions and role of glomerular 
pericytes, more commonly referred to as mesangial cells, in the pathogenesis of 
renal disease. This is largely due to the relative ease with which these cells can be 
identified, isolated and cultured in vitro from humans and mice using differential 
sieving techniques. In contrast, tubulointerstitial pericytes are more challenging to 
isolate. Only relatively recently have transgenic mouse models facilitated their 
isolation in vitro. Here, the two renal pericyte populations will be considered 
separately. 
 
It was first suggested 20 years ago by Schlondorff that glomerular mesangial cells 
represented a specialised form of microvascular pericyte (180). Mesangial cells play 
a central role in stabilising and maintaining the structural architecture of the 
glomerulus and exhibit many of the features associated with pericytes at non-renal 
sites described above (150).  Mesangial cells differentiate from primitive pericytes 
during development and have been shown to participate in the subdivision of the 
capillary network during glomerulogenesis (181).  Crosstalk between mesangial cells 
and the glomerular endothelium is essential to maintain vascular structure, and this 
again involves PDGF signalling. PDGF-B and PDGFR-β null mice are non-viable and 
exhibit markedly abnormal glomerular structure with an absence of mesangial cells 
(182, 183).  
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In the glomerulus, mesangial cells form a central stalk and constitute approximately 
30% of all glomerular cells (180). They express recognised surface markers such as 
PDGFRβ and CD90. In health, mesangial cells deposit ECM, predominately type IV 
collagen, laminin and fibronectin, a process that becomes dysregulated in many of 
the glomerulonephropathies (7, 180). The contractile properties of mesangial cells 
allow them to fine tune glomerular filtration. They can thus directly sense and 
respond to changes in capillary stretch which allows modulation of single nephron 
glomerular filtration rate (184). Mesangial cells are also capable of immune 
surveillance. Human mesangial cells can acquire a monocyte/macrophage 
phenotype (185). Also, mesangial cells may represent a glomerular mesenchymal 
stem cell niche since, like other pericytes, they exhibit pluripotency in vitro and can 
be reprogrammed to form pluripotent stem cells that form teratomas if injected into 
immuno-deficient mice (186). 
 
1.7.1.8.4 Peri-tubular pericytes  
Outside of the glomerular compartment pericytes are found on peri-tubular capillaries 
of the interstitium (13). Our understanding of the role that pericytes play in the 
pathogenesis of disease has expanded rapidly in recent years. Reports in the 
literature dating back 10 years focused on the role pericytes play in regulating 
medullary blood flow (187). While this remains an active area of research (188), more 
recently a key role for pericytes in the pathogenesis of CKD has been proposed.  
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Elegant studies by Lin et al, used novel transgenic mouse models that allowed the 
tracking and phenotyping of renal pericytes in several different murine models of 
kidney disease (51). Using a mouse that expresses green fluorescent protein (GFP) 
under regulation of the collagen 1α1 promoter, they demonstrated that pericytes and 
peri-tubular fibroblasts contributed significantly to interstitial αSMA+ activated stromal 
fibroblast (myofibroblast) populations in experimental renal fibrosis. Careful tracking 
and kinetic modelling studies demonstrated that, in response to injury, collagen1α1+ 
pericytes upregulated classical pericyte markers (PDGFRβ, αSMA), upregulated 
collagen deposition and detached and migrated away from the underlying 
endothelium. Later studies by the same group have demonstrated that this process is 
accompanied by microvascular rarefaction, as loss of pericytes from the vasculature 
destabilises the vessel and leads to a failure of reparative angiogenesis (95). 
 
One surprising observation from these studies was that despite severe renal injury, 
epithelial cells did not express collagen transcripts. Therefore they are unlikely to be 
a source of myofibroblasts, drawing the process of EMT in kidney disease into doubt 
(51).  Additional fate tracking studies were performed by Lin et al to support the initial 
studies. Renal epithelial cells were genetically tagged using Six2-cre and HoxB7-cre 
drivers. Mesenchymal cells were labelled using the FoxD1-cre driver during 
embryonic development. Together Six2 and HoxB7 labelled the epithelium and 
collecting duct epithelium respectively. FoxD1 was expressed by mesenchymal cells 
and tagged all cells destined to become pericytes. Mice were then backcrossed with 
appropriate floxed reporter mice strains and the fate of the renal epithelium and 
pericytes in response to renal injury observed in two different models (51, 143). 
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FoxD1+ cells were found to represent the same population of cells as the 
collagen1α1 tagged cells reported previously; this population expanded rapidly to 
form the majority of the αSMA+ myofibroblasts seen in response to injury. No tagged 
epithelial cells were seen to co-express αSMA or the EMT marker FSP-1 within the 
interstitium in response to injury. In vitro Six2 tagged epithelial cells could be induced 
to express αSMA and FSP-1. They also lost expression of E-cadherin, an epithelial 
cell marker, in response to stimulation with the pro-fibrotic growth factor TGFβ thus 
suggesting that EMT may represent an in vitro phenomenon (142, 143). These 
experimental findings were subsequently replicated by two independent groups (88, 
89) and have generated much debate within the renal literature.  
 
Targeting endothelial-pericyte crosstalk may prove a valuable tool to treat renal 
fibrosis. Pericytes are seen to detach from the interstitial capillary within hours of the 
induction of renal injury (51). As discussed previously pericyte investment in the 
endothelium is essential for the maintenance of vascular stability. Microvascular 
rarefaction will itself drive fibrosis by leading to tissue hypoxia (144). Thus pericyte 
detachment has a double impact for kidney disease. Not only do pericytes become 
myofibroblasts that deposit matrix leading to fibrosis, but their detachment from the 
endothelium also exacerbates tissue hypoxia and damage. Stabilising endothelial 
pericyte crosstalk in CKD may therefore be an effective therapeutic strategy.  
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1.7.1.9 Stem cells 
Haemopoietic (HSC) and mesenchymal (MSC) stem cells have both been implicated 
in the response to renal injury and repair. Resident pericytes (see above) may 
represent an MSC niche in solid organs such as the kidney (145). Circulating stem 
cells are reported to migrate into the kidney in response to damage and are able to 
transdifferentiate into both glomerular and tubular cell populations (189).   
 
Human studies have reported the presence of Y-chromosome positive TEC in renal 
female grafts transplanted into male recipients (190, 191). Animal studies have 
confirmed these observations and suggest recruitment to the kidney of HSCs is 
under the control of the stromal cell derived factor-1 (SDF-1) /CXCR4 signalling axis 
(192). Although incompletely understood, blockade of this axis leads to worsening 
renal fibrosis (193).  
 
MSCs have been shown to attenuate renal fibrosis through immune modulation and 
these cells can secrete a number of anti-inflammatory factors such as prostaglandin 
E2 and interlukin10 (IL-10) (194).  Infusion of MSCs attenuates renal fibrosis in a rat 
remnant kidney model of injury (195). Similarly, Ninichuk et al demonstrated a 
reduction in interstitial fibrosis following the infusion of MSCs in a murine model of 
Alport’s disease (196). Perhaps more importantly, this intervention failed to delay the 
progression of CKD in the studied animals.  
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1.7.2 Non-cellular mediators 
1.7.2.1 Extracellular matrix 
The ECM is involved in supporting and fine-tuning the fibrotic response to injury 
(197). In the kidney as injury evolves, the expanded interstitial space created as a 
consequence of tubular atrophy is filled with fibrillar matrix. This comprises of 
predominately collagens type I and III together with fibronectin (198) although type IV 
collagen, a remnant of  basement membrane destruction, is also present.   
 
The ECM is stabilised, through a process of cross-linking by tissue 
transglutaminases (TTG), making it resistant to degradation by tissue proteases 
(199). Elevated levels of TTG in human kidney disease have been reported and are 
found to correlate with the disease severity (200). Mice deficient in TTGs have a 
reduction in renal fibrosis following injury (201).  ECM can directly mediate fibrosis, 
through the interaction with integrins expressed on fibroblasts (119), whilst fibronectin 
can act as a scaffold for the deposition of pro-inflammatory cytokines (202).  
Consequently areas of fibrosis within an inflamed kidney can enter a self-regulating 
pro-fibrotic cycle.  Intriguingly, cleaved ECM fragments have also been suggested to 
act as chemotractants in vivo. Using a murine model of inflammatory lung disease, 
Weathington et al demonstrated that a cleavage product of collagen I can mimic the 
effect of CXC-chemokine ligand 8 on neutrophils (203). 
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1.7.2.2 Tissue proteases 
Proteases are important modifiers of ECM. They can attenuate renal fibrosis by 
facilitating matrix degradation, but also can be detrimental through their cleavage of 
matrix and non-matrix substrates leading to the release of fibrotic growth factors and 
the induction of EMT (204). Two main families of molecules are described in the 
literature. The matrix metalloproteinases (MMPs) with their antagonists the tissue 
inhibitors of matrix metalloproteinases (TIMPs) (205) and the plasminogen-plasmin 
proteases (206). Dissecting the role proteases play in renal fibrosis is challenging.  
 
The activated protease plasmin is formed by the cleavage of plasminogen by tissue 
type plasminogen activator (tPA) or urokinase type plasminogen activator (uPA). 
These activator proteins are antagonised by plasminogen activator inhibitor-1 (PAI-1) 
(207). Plasmin degrades the matrix proteins fibronectin and laminin and can activate 
MMPs (207). It has also been suggested to promote the development of activated 
stromal cells through the destruction of the tubular basement membrane and EMT 
(208).  
 
Twenty five MMPs are currently recognised (209) and are involved in tissue 
development and remodelling. Although originally it was thought they only targeted 
matrix proteins, it has also been shown that they are capable of cleaving cell 
adhesion molecules such as integrins and growth factors such as TGFβ (210). In 
contrast, only 4 TIMPS are described; these endogenous tissue enzymes bind and 
inactivate MMPs. The best characterised MMPs in renal fibrosis are MMP 2 and 9, 
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proteases capable of degrading collagen IV. Blockade/removal of MMP 2 and 9 has 
been suggested to be both protective (204, 211) and harmful (212) following renal 
injury. Similarly mice deficient in TIMP 3 (213) spontaneously develop renal fibrosis 
but TIMP 1-/- mice are not more susceptible to the development of fibrosis than 
wildtype animals (214).  
 
1.7.2.3 Chemokines 
Chemokines are a group of chemotactic cytokines that attract leukocytes in response 
to inflammation through binding to G protein-coupled receptors (215) and are thought 
to play a pivotal role in the development of chronic renal injury (216, 217). 
Chemokines are divided into four families (CCL, CXCL, CX3CL and CL) based on 
the distribution of cysteine residues within their molecular structure (218). Endothelial 
cells, podocytes, TEC, fibroblasts and mesangial cells of the kidney are all capable of 
producing chemokines in response to injury (219), although chemokines are also 
secreted as part of normal homeostasis. 
 
A switch from the expression of CXCL chemokines such as IL-8, to CCL chemokines 
such as MCP-1 is thought to accompany the transition from acute to chronic renal 
inflammation (215, 220). Increased urinary levels of CCL chemokines are associated 
with progressive CKD and correlate with macrophage infiltration and inversely 
correlate with renal fibrosis and function in humans (31). Functional blocking studies 
in animals, targeting CCL chemokines, reduce leucocyte infiltration, proteinuria and 
tissue damage in response to injury (221, 222). 
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1.7.2.4 Growth factors 
Growth factors, as their name suggests, are capable of stimulating cellular growth, 
proliferation and differentiation and thus represent a promising treatment target for 
renal fibrosis (223). Multiple growth factors have been ascribed to play a role in the 
aetiology of renal scarring. These include: transforming growth factor alpha and beta 
(TGF-α, TGF-β) (139); bone morphogenic protein 7 (BMP-7) (224); connective tissue 
growth factor (CTGF) (225); platelet derived growth factor (PDGF) (226); vascular 
endothelial growth factor (VEGF) (223); fibroblast growth factor 2 (FGF-2) (227) and 
hepatocyte growth factor  (HGF) (228). Here I will focus on three of the best 
described growth factors implicated in the pathogenesis of renal fibrosis TGFβ, 
PDGF and VEGF. 
 
1.7.2.4.1 TGFβ 
TGFβ is thought to play an essential role in the initiation and progression of fibrosis 
and was one of the first pro-fibrotic factors described (229).  Three isoforms of TGFβ 
are recognised (β1, β2 and β3), with the majority of the published literature focusing on 
TGFβ1 (230). Indeed, polymorphisms in the TGFβ1 gene have been proposed to 
predispose to the development of CKD (231). Upregulation of TGFβ is found in 
animal and human models of CKD (230); and inhibition of TGFβ in animal models of 
renal fibrosis is protective (232). Consequently TGFβ is an excellent candidate 
biomarker (233) of kidney fibrosis and a target for treatment.  However, the 
ubiquitous expression of TGFβ and its pivotal immunoregulatory role may preclude 
long-term blockade in humans. 
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Latent TGFβ is secreted as a homodimer that binds to ECM and subsequently 
undergoes significant posttranscriptional regulation (223). Activation occurs through 
cleavage by tissue proteases or by integrin binding that induces activated TGFβ to 
bind to cell surface receptors driving phosphorylation of downstream regulators of the 
Smad pathway (234). Activation of Smads causes their translocation to the nucleus 
where they function to control gene expression. Smad signalling in the normal kidney 
is tightly constrained by transcriptional co-repressors, including snoN, Ski and TGIF. 
Yang et al have demonstrated that SnoN and Ski are progressively diminished in 
fibrotic kidneys raising the possibility that the loss of Smad antagonists serves to 
amplify the TGF-β response to injury (235). 
 
1.7.2.4.2 VEGF 
VEGF is chemotactic for monocytes but primarily functions as an endothelial cell 
mitogen involved in promoting angiogenesis, vascular stability and permeability 
(144). The VEGF family includes five members (VEGF-A, -B, -C, -D and placental 
growth factor (PIGF)) that exist as hetero and homodimers. Each member binds and 
differentially activates one or more of 4 receptors. To complicate matters further, 
there are an extensive number of VEGF splice variants. 
 
The VEGF growth factor system is highly complex and our understanding of its 
involvement in renal disease is limited. VEGF is known to be upregulated in response 
to hypoxia via the HIF system, a process that occurs rapidly to drive adaptive 
angiogenesis (144). Human studies have suggested that VEGF is upregulated in 
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(32), and may protect against renal fibrosis (44). An assertion supported by animal 
models using VEGF (236) and VEGF receptor antagonists (95). This protective role 
appears to be mediated through vascular stabilisation and protection against 
microvascular rarefaction, although a reduction in monocyte recruitment has also 
been reported (95). In contrast, over expression of VEGF in animal models (237) and 
treatment with VEGF antagonists (238) in humans can also be detrimental to the 
kidney. 
 
1.7.2.4.3 PDGF 
In contrast to VEGF, our understanding of the PDGF system is further advanced. 
PDGF is a chemotractant and mitogen for stromal cells, comprising four isoforms 
(PDGF-A, -B, -C and -D) (239, 240). PDGF-A and –B are secreted as homo or 
heterodimers and bind to ECM. PDGF-C and –D are secreted only as homodimers. 
Similarly, PDGF receptors (PDGFR) are dimers composed of α and/or β chains. 
PDGF-A can bind the α domain only but PDGF-B binds all receptor types. PDGF-C 
binds PDGFR-αα or -αβ whilst PDGF–D binds PDGFRββ. Binding to the PDGFR by 
its cognate ligand leads to phosphorylation of the receptor and activation of tyrosine 
kinase dependent transcription factors. 
 
In the adult kidney PDGFR –α and β are expressed by mesangial cells of the 
glomerulus and interstitial pericytes. The importance of the PDGF signalling pathway 
in renal development and function is evidenced by data from genetically altered mice. 
Mice deficient in PDGF-A and –B die prenatally. Furthermore, both PDGF-B and 
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PDGFR−β deficient mice have defective formation of the glomerular mesangium, a 
phenotype that can be replicated postnatally in young animals using functional 
blocking antibodies. PDGF, particularly PDGF-B, is also crucial for endothelial 
cell/pericyte crosstalk and the maturation and stabilisation of blood vessels (176), 
and is found to be upregulated in a diverse array of animal models and human 
cohorts of renal disease. PDGFR-β blockade is protective against microvascular 
rarefaction and fibrosis (95). 
 
1.8 CD248 
1.8.1 Identification 
CD248 (also known as Endosialin, Tumour endothelial marker-1 (TEM1), CD146L1) 
belongs to a larger family of proteins that are all implicated in inflammation, tissue 
remodelling and repair (158). The other family members are discussed individually in 
the text below. CD248 was first described in the cancer literature almost 20 years 
ago when it was recognised by a panel of monoclonal antibodies raised against 
surface antigens on human foetal fibroblasts (241), as being expressed on tumour 
but not normal tissue. 
 
CD248 was initially named Endosialin reflecting preliminary data suggesting it was 
expressed exclusively on activated tumour endothelium. Crucially, it was not seen on 
normal endothelium, thus making it an attractive target for the development of novel 
anti-angiogenic therapeutics. Further support for the expression of CD248 by 
activated endothelial cells came a decade after its first identification. St Croix et al 
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used serial expression of gene analysis (SAGE) to identify CD248 as the most highly 
upregulated gene transcript on the tumour endothelium of colon carcinoma, when 
compared to adjacent normal endothelium (242).  This report was followed by a 
number of publications describing its expression on endothelial cells in different 
tumour types (163, 243-247). 
 
Despite these early reports it is now recognised that CD248 is expressed by stromal 
pericytes and fibroblasts and not by endothelial cells. More recently in humans, 
CD248 has been shown to be expressed by a population of CD8+ T cells and also a 
population of vascular leukocytes has been reported (248, 249). The confusion 
surrounding the cellular expression of CD248 arises due to technical problems in 
early studies. St Croix et al isolated endothelial cells from human malignancies using 
beads designed to bind to CD146 (242). Although endothelial cells express CD146, it 
is also expressed by pericytes, epithelial cells, smooth muscle cells and 
myofibroblasts (250). Early localisation of CD248, in tissue sections from human 
malignancies used in situ hybridisation (17) and immunohistochemistry (242) but did 
not employ dual labelling techniques. This made the discrimination between pericytes 
and the underlying endothelium impossible (163). 
 
In addition to the technical limitations described above, it should also be noted that 
CD248 cannot be detected, either at the mRNA or protein level, on endothelial cells 
in vitro and attempts to induce expression using pro-angiogenic factors have proved 
unsuccessful (163). In contrast, stromal fibroblast lines in vitro express high levels of 
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CD248. Doubling labelling confocal microscopy has also confirmed expression of 
CD248 by pericytes and fibroblasts but not by endothelial cells in vivo (157).  
 
1.8.2 Structure of CD248  
CD248 is a type 1 transmembrane glycoprotein that is highly conserved between 
mice and humans (251, 252). In humans, CD248 is coded for by an intronless gene 
located on chromosome 11. The gene has an open reading frame of 2274bp and 
encodes a protein 757 amino acids long with a predicted molecular mass of 80.9 
KDa. In mice CD248 is coded for on chromosome 19 with an open reading frame of 
2295bp encoding 765 amino acids with a predicted molecular mass of 92 (251).  
 
Structurally CD248 (Figure 1.4) is formed from an N-terminal C-type lectin like 
domain, a complement control (sushi) domain, 3 epidermal growth factor (EGF)-like 
repeats, a mucin like region, a short transmembrane segment and a short 
cytoplasmic tail. The core protein is highly sialyted with O-linked oligosaccharides 
(241). Opavsky et al have identified 3 potential phosphorylation sites in the 
cytoplasmic tail that could participate in signal transduction (251). 
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Figure 1.4 
 
CD248 family members 
 
CD248, CD141, CD93 and Clec14A belong to a family of proteins that are all implicated in inflammation, tissue 
remodelling and repair. They exhibit shared homology in their extracellular globular domains, but with each 
molecule having a different number of EGF modules. The Ser/Thr/Pro-rich mucin-like region also varies greatly 
between the molecules [Adapted from (253)]. 
 
 
 
1.8.3 CD248 family members 
Proteins that contain a C-type lectin-like domain can be divided into 14 family groups 
based on sequence and analysis of domain organisation (254). In this classification 
the CD248 family of proteins represents group 14. In addition to CD248 group 14 
includes the proteins thrombomodulin (CD141), CD93 (complement 1q receptor 
protein (C1qRp)), and C-type lectin domain family member 14A (Clec14A). The 
globular domains of these 4 proteins is highly conserved in mice and humans, 
although the overall amino acid sequence varies widely between individual family 
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members (253). All members appear to have a functional role in cell adhesion and 
the regulation of inflammation and cancer. 
 
CD141 is a well characterised natural anticoagulant (255) expressed throughout the 
vasculature on the  endothelium. CD141-/- mice develop spontaneous, fatal 
thrombotic events in both the arterial and venous system (256). Beyond its role as a 
natural anticoagulant, CD141 also mediates neutrophil adhesion to the endothelium 
in response to exogenously administered endotoxin (257). Further through its ability 
to sequester thrombin, CD141 can modulate inflammation (258). A gene duplication 
of CD141 has been proposed to give rise to CD93. Both genes are expressed on 
chromosome 20 in humans and exhibit a high degree of sequence homology (259, 
260).  
 
CD93 is expressed by myeloid and endothelial cells, particularly during 
embryogenesis and has also been reported to be expressed by mesenchymal stem 
cells (261-263). It is recognised to participate in a number of innate immune defence 
mechanisms through its interaction with C1q, a subcomponent of complement factor 
C1, including phagocytosis, cytokine modulation and generation of superoxide 
release by neutrophils (255). 
 
CLEC14A is an endothelial cell marker implicated in tumour angiogenesis (264). It is 
also thought to mediate cell-cell adhesion through its C-type lectin domain (265). 
Mura et al have demonstrated that CLEC14A is functionally important in vascular 
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development in zebrafish and, by using in vitro assays, showed that it facilitates 
endothelial cell migration and tube formation. CLEC14A expression is also linked to 
low shear stress suggesting expression occurs in response to the disorganisation of 
the vascular network that is often described within tumour stroma (264). 
 
1.8.4 Renal expression of CD248 
At basal levels in the adult human and mouse kidney, CD248 is expressed on 
mesangial cells in the glomerulus. In human renal cell carcinoma (RCC) expression 
is significantly increased and large rafts of CD248+ fibroblasts can be seen within the 
interstitium (266). Apart from these observations, little else is known about the 
expression and function of CD248 in renal disease. 
 
1.8.5 Regulation of stromal CD248 expression in vitro 
Opavsky et al have demonstrated that in vitro, CD248 expression is cell density 
dependent and suggested that gene expression occurs in response to peri-cellular 
hypoxia (251). This suggestion is supported by studies performed by Ohradnova et al 
who identified a HIF2α response element in the promoter region of CD248 (267). 
Furthermore, HIF2α appears to be able to both directly activate CD248 through 
binding to the promoter region, and indirectly activate it through interactions with the 
hypoxia dependent transcription factors SP1 and ETs-1. 
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1.8.6 Ligands and downstream signalling pathways for CD248 
Our understanding of the ligands for CD248 and downstream signalling pathways is 
incomplete. In vitro studies have shown that the endothelial basement membrane 
proteins fibronectin, collagen type I and collagen type IV can act as specific ligands 
for CD248 (268). Cells transfected with CD248 exhibit enhanced adhesion to 
fibronectin and enhanced migration through matrigel. This effect is blocked with 
humanised antibodies directed against CD248. In addition, Becker et al have shown 
that a C-terminal fragment of the CD248 extracellular domain binds the galectin 
binding protein Mac-2BP/90K (269). As well as binding to galectin 3, Mac-2 BP/90K 
also binds to ECM components including collagens V and VI through the same C-
terminal fragment. In vivo analysis of Mac-2 BP/90K and CD248 expression in 
malignant tumours and in vitro studies suggest that CD248 and Mac-2 BP/90K may 
mediate cellular positioning signals that act to separate the epithelial and 
mesenchymal compartments of malignant tumours. 
 
The downstream signalling pathways of CD248 are linked to PDGF signalling (166, 
167). Tomkowicz et al have demonstrated that CD248 regulates pericyte proliferation 
in vitro through effects on PDGF receptor signalling. Knock down of CD248 using 
siRNA, reduced PDGF-BB mediated proliferation. This effect was found to be 
mediated through phosphorylation of the MAP kinase ERK-1/2 and the subsequent 
downstream expression of the transcription factor c-fos. In these studies no 
difference in PDGFR-β surface expression following CD248 knockdown was 
detected.  
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1.8.7 CD248 transgenic mice  
Transgenic mice in which CD248 is deleted have been generated in order to 
understand its function and expression in vivo. Huang et al created a CD248 knock in 
animal in which the normal CD248 gene was disrupted and replaced with a lacZ 
reporter to detect CD248 in the developing and adult mouse (270). CD248 was first 
detectable in the heart, the umbilical vessels and the vasculature at E9.5; and from 
E10.5 to E14.5 CD248 was seen in the whisker follicles, the eye and the lung. In the 
kidney, CD248 expression was observed in the glomerulus and primitive interstitium 
from E16.5.  Post-natally CD248 expression decreased in most solid organs. High 
levels of expression persisted in the renal glomerulus and in the uterus, where 
expression pattern varied according to the oestrous cycle. These murine 
observations of the basal expression of CD248 parallel earlier studies using archived 
normal human tissue samples (242, 245). 
 
Two different approaches to generating CD248-/- mice have been reported by 
independent investigators. Nanda et al developed a transgenic animal where CD248 
was constitutively removed by targeted homologous recombination (271). These 
animals develop normally and have normal postnatal growth. An alternative approach 
to the generation of CD248 transgenic mice was reported by Maia et al (272, 273). In 
addition to generating animals where the CD248 gene is floxed to allow backcrossing 
to cre reporter strains, they also generated mice with CD248 lacking the short 
cytoplasmic domain (CD248CyD/CyD).  Again these animals develop normally. The 
results of experimental models using these animals are discussed below. 
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1.8.8 CD248 expression in vivo 
In vivo murine models have demonstrated that CD248 is anatomically and temporally 
regulated with high levels of expression found in the embryo and newborn tissue, and 
low levels in normal adult tissues (158).  In humans and mice, CD248 expression is 
upregulated on fibroblasts and pericytes found in inflammatory and cancer stroma 
suggesting a role in tissue remodelling and repair (157, 274).  
 
Carcinomas from a diverse range of malignancies have been reported to express 
CD248 on the tumour vasculature including breast, colon, stomach, pancreas, liver 
and lung (241). A number of authors have studied the link between CD248 
expression in malignant tumours and clinicopathological outcome measures in 
humans (246, 275-277). Models in CD248-/- mice have shown that if tumours are 
implanted in the abdominal cavity, there is impaired tumour growth, invasion and 
metastasis, highlighting a critical role for CD248 in determining tumour behaviour 
(271). Furthermore, there was a significant increase in the number of smaller, 
immature vessels (<50 µm diameter) in tumours from CD248-/- mice compared to 
those from wildtype animals. Studies using CD248CyD/CyD mice have highlighted the 
importance of the cytoplasmic domain of CD248 in mediating tumour growth (273). In 
contrast, no defects were seen when wound healing assays were performed in the 
skin of CD248-/-mice (271). 
 
CD248 is also implicated in lymphoid tissue remodelling in response to inflammation 
and in the pathogenesis of inflammatory arthritis. Lax et al used a salmonella-
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induced model of splenic enlargement to explore the expression of CD248 during the 
initiation and resolution of inflammation (165). CD248 defined a discreet 
subpopulation of stromal cells within the tissue. CD248 was maximally expressed at 
the peak of splenic enlargement and expression was downregulated as injury 
resolved. Similarly, CD248 expression is required for efficient lymph node expansion 
in response to immunisation (164), via effects on cell proliferation and migration, but 
not differentiation in vivo and in vitro. 
 
In inflammatory arthritis CD248 is expressed in synovial fibroblasts isolated from 
patients with rheumatoid arthritis (163, 272). Maia et al demonstrated using a murine 
model of arthritis, that CD248 contributes to synovial hyperplasia, fibrosis and 
leucocyte accumulation in inflammatory arthritis and, as such, CD248 may represent 
a target for the treatment of arthritis. 
 
1.8.9 Origin of CD248+ cells in inflammatory stroma 
The origin of CD248+ cells in inflammatory stroma remains poorly defined. Intuitively 
they may arise from local resident stromal cells. However CD248 has been found on 
a subset of vascular leucocytes that are able to integrate into, and form blood vessels 
in vivo (278). Similarly, Bagley et al have reported an endothelial progenitor cell 
population that expresses CD248 (279); and it is also highly expressed by MSCs 
isolated from bone marrow (266, 280). Our group has also reported that CD248 is 
expressed on a small population of naive CD8+ human T cells and regulates 
proliferation (281). These observations, however, may not be so surprising when 
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framed in the context of the tissue pericytes potentially representing a MSC niche 
(145). 
 
1.8.10 CD248 as a therapeutic target 
CD248 is an attractive therapeutic target. Expression is low in healthy tissue but 
upregulated in diseased tissue at times of remodelling. It is expressed at the cell 
surface and can therefore be targeted by circulating neutralizing or activating 
antibodies. Rettig et al has previously demonstrated that monoclonal antibodies to 
CD248 are bound and internalised by surface receptors (241). Similarly, Rouleau et 
al have conjugated saporin to anti-CD248 antibodies and inhibited cell growth in vitro 
(282). Indeed, a monoclonal anti-human CD248 antibody (MORAb-004) (268) is 
currently undergoing phase 1 clinical trials for the treatment of solid tumours 
(ClinicalTrials.gov identifier: NCT008470544). 
 
1.9 Summary 
Drawing all of the ideas described above together, it is apparent that CD248 is 
involved in stromal and vascular remodelling, key processes implicated in the 
pathogenesis of renal fibrosis and CKD. CD248 is expressed on resident renal 
pericytes; a cell population that is emerging as a key mediator of microvascular 
rarefaction and as a source of myofibroblast progenitors. Our understanding of the 
distribution and function of CD248 in the human kidney in health and disease is 
incomplete. Therefore the aim of this thesis was to examine the role of CD248 in the 
pathogenesis of renal fibrosis. 
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1.10 Thesis hypothesis  
CD248 expressed on renal stromal cells is involved in the pathogenesis of renal 
fibrosis 
Aims 
1. To characterise the expression of CD248 in human kidney disease. Can 
CD248 be used to predict renal outcome? 
2. To examine the cellular origin and function of CD248 in murine models of 
renal fibrosis? Does the constitutive removal of CD248 exacerbate/ameliorate 
the development of renal injury? 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Methods for Chapter 3: Human studies 
Unless otherwise stated all reagents used in this thesis are purchased form Sigma 
Aldrich, Poole, UK. 
2.1.1 Antibodies 
The primary, secondary and isotype control antibodies used for the human studies 
are detailed in Tables 2.1, 2.2 and 2.3. 
Table 2.1 Isotype controls 
Isotype Supplier Working dilution 
Mouse IgG1 Dako Appropriate to primary antibody 
Mouse IgG2a Dako Appropriate to primary antibody 
Polyclonal rabbit R&D Systems Appropriate to primary antibody 
 
Table 2.2 Primary antibodies 
Specificity Isotype Clone Supplier Working dilution 
CD31 mouse IgG1 JC70A Dako 1:20 
CD45 polyclonal rabbit polyclonal Abcam 1:150 
CD248 mouse IgG1 B1/35 In house 
IHC 1:600 
WB 1:6000 
αSMA mouse IgG2a 1A4 Sigma 1:50 
βactin polyclonal rabbit polyclonal Sigma 1:5000 
Cytokeratin mouse IgG1 MNF116 Dako 1:50 
Desmin mouse IgG1 D33 Dako 1:50 
Vimentin mouse IgG1 V9 Dako 1:50 
 
 
Table 2.3 Secondary antibodies 
Specificity Conjugate Host Supplier Working dilution 
Anti-mouse IgG1 Alexa488 goat Invitrogen 1:1000 
Anti-mouse IgG2a Alexa555 goat Invitrogen 1:1000 
Anti-rabbit IgG HRP goat Amersham 1:10000 
Anti-mouse IgG HRP goat Amersham 1:10000 
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2.1.2 Human cell lines 
Following NRES ethical approval (REC approval number 08/H1203/8) and under the 
regulations described within the Human Tissue Act 2004, human renal fibroblasts 
were isolated from the normal pole of nephrectomy samples removed for the 
treatment of malignant disease as described below. Conditionally Immortalised 
human glomerular endothelial cells (GEC) and podocytes were a kind gift from Dr 
Simon Satchell (University of Bristol, UK). Human Umbilical Vein Endothelial Cells 
(HUVEC) were a gift from Mrs Sahithi Panchagnula and were isolated from human 
umbilical cords (REC approval number 05/Q2708/30) obtained from the Birmingham 
Women’s Hospital, UK. 
 
2.1.3 Isolation of human renal fibroblasts 
Human renal fibroblasts were isolated from fresh nephrectomy tissue using the 
method of Grimwood (283). Six-well plates were coated with 2ml of 1% gelatin 
solution and incubated for 30 minutes at 37oC. Residual gelatin was aspirated and 
the plates gently washed twice with phosphate-buffered saline (PBS). Nephrectomy 
tissue was collected from the Pathology Department of the Queen Elizabeth hospital 
(QEH) and transported to the laboratory in ice cold Dulbecco’s Modified Eagle’s 
Medium (DMEM).  Tissue was washed in ice cold PBS to remove any residual blood 
and the renal cortex was dissected away from the medulla under sterile conditions. 
The cortex was then minced using two scalpel blades. The minced tissue was 
transferred into the gelatin coated 6-well plate. Approximately 0.5-1 mm3 of tissue 
was added to each well. The tissue was adhered to the plate by making ‘cross-wise’ 
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scratches into the surface of the plate with a scalpel blade. Enough complete 
fibroblast medium was then added to cover the tissue. Samples were incubated 
overnight at 37oC with 95% oxygen and 5% CO2. The next day cultures were 
supplemented with an additional 2ml of complete fibroblast medium. Explants were 
incubated for 72 hours to allow for the initial outgrowth of cells from the tissue. A full 
medium change was then performed. Medium was changed twice weekly until 
cultures reached confluence. Once confluence was reached cultures were passaged 
into a T25 flask.  
 
2.1.4 Cell culture 
Cells were grown at 37 oC in an atmosphere of 5% carbon dioxide. The media 
recipes used to culture individual cell lines are detailed in Table 2.4. Cells used for 
the in vitro studies described were all between passages 2 to 8 with the exception of 
the immortalized cell lines that were used until passage 40. 
 
2.1.5 Passaging 
Cells were passaged when confluence was reached. Cells were passaged by 
washing in 2.5ml of 0.02% EDTA (Ethylenediaminetetraacetic Acid Disodium Salt), 
followed by the addition of 2.5ml of 1x Trypsin/EDTA for 1-2 minutes at 37 oC. Firmly 
tapping the flask dislodged the cells from the surface. The trypsin was neutralised 
with 5mls of complete medium and cells were centrifuged at 300 g for 6 minutes at 
room temperature. After discarding the supernatant the pellet was re-suspended in 1 
ml fresh medium and cells counted in a haemocytometer. Cells were reseeded in 
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T75 culture flasks at a dilution of 1:3, or into chamber slides at 10,000 cells per well. 
The cells were incubated at 37 oC until confluence was achieved. 
 
Table 2.4 Media recipes for human cell line 
Cell type Ingredient Volume Final concentration Source 
 
Renal fibroblasts 
 
 
Dulbecco’s modified eagles 
medium (DMEM) 395mls - Sigma 
Fetal calf serum (FCS) 
 100mls 20% Lonza 
Gluatmine,penicillin, 
streptomycin (GPS) solution 
 
5mls 
1.75mM 
87U/ml 
87µg/ml 
Sigma 
 
HUVEC 
Medium 199 
 100ml - Gibco 
Hydrocortisone 
 10µl 1µg/ml Sigma 
Penicillin and streptomycin  1ml 1mM Sigma 
Endothelial growth factor (EGF) 10µl 1ng/ml Sigma 
L-Glutamine 1ml 20mM Sigma 
Amphotericin 1ml 2.5µg/ml Sigma 
FCS 20ml 20% Sigma  
 
GEC 
 
 
 
Endothelial growth medium 500ml  
 
 
 
Endothelial growth  
medium kit 
(EBM-2) 
 
 
 
 
 
Lonza 
Human fibroblast growth factor 
β (hFGF-β) 
2ml 
Gentamicin sulphate, 
Amphotericin-B 
500µl 
FCS 25ml 
Insulin like growth factor-1 500µl 
Hydrocortisone 200µl 
Vascular endothelial growth 
factor (VEGF) 
500µl 
EGF 500µl 
 
Podocytes 
Roswell park memorial institute 
(RPMI) 1640 medium 
100ml - Sigma 
FCS 10ml 10% Sigma 
Penicillin and streptomycin  1ml 1mM Sigma 
L-Glutamine 1ml 20mM Sigma 
ITS solution 1ml 10µg/ml Insulin  
5.5µg/ml Transferrin  
5ng/ml Sodium selenite  
Sigma 
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2.1.6 Freezing of cell cultures for long term storage 
Trypsin and EDTA were used to remove the cells from the flasks as described above. 
The cells were pelleted at 300 g for 6 minutes at room temperature to form a pellet 
that was then re-suspended in FCS with 10% Dimethyl sulfoxide (DMSO).  
 
2.1.7 Characterisation of human renal fibroblasts 
Cells were characterised using phase contrast microscopy to assess morphology and 
confocal microscopy to look for the expression of recognised cell markers.  To 
assess morphology cells were seeded into 6 well plates (Corning) at 10,000 cells per 
well and were allowed to grow to confluence at 37oC. Medium was removed, and 
each well washed 3 times with PBS to remove any detached cells or debris. Cells 
were then covered with medium. Phase contrast images were captured using an 
IX71 inverted microscope (Olympus). 
 
For confocal microscopy cells were seeded in 8 well glass chamber slides (BD 
Falcon) at 10,000 cells per well and were allowed to grow to confluence at 37oC. 
Medium was removed, and each well washed three times using 200µl PBS. The 
plastic well chambers were separated from the glass slide leaving adherent cell 
cultures. Fixation was achieved by adding 100µl of ice-cold methanol to each culture 
on the slide for 10 minutes at -20oC. The slides were then washed by immersion in 
PBS for 10 minutes with gentle agitation. The primary antibody was then added in 
50µl of PBS + 2% BSA and 1% FCS, and incubated overnight at 4oC. Slides were 
again washed in PBS and the secondary antibody was then added in PBS, 
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containing 2% BSA and 1% FCS, for 1 hour at room temperature before being 
washed in PBS and mounted in SlowFade (Invitrogen).  Slides were visualised using 
a Zeiss confocal LSM 510 microscope (Zeiss, Germany) and processed using Zeiss 
LSM Image Examiner software (Zeiss). 
 
2.1.8 Reverse transcription polymerase chain reaction 
Cells were grown to confluence in 6 well plates. A Qiagen RNeasy Mini Kit (Qiagen, 
Valencia, CA) was used to isolate RNA according to the manufacturer's protocol. 
cDNA was generated using a TaqMan® Reverse Transcription (Applied 
Biosysystems).  PCR was performed using the primers shown in Table 2.5-2.8 (Alta 
Bioscience). A total of 10µl of sample and 2µl of 6x loading buffer were run at 100 
volts on a 2% agarose gel containing ethidium bromide. 
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Table 2.5 Reverse transcription mix 
Ingredient Volume Concentration 
10x RT buffer 1µl 1x 
25mM Magnesium chloride 2.2 µl 5.5mM 
dNTPs (10mM each) 2 µl 500µM 
Random hexamers 0.5 µl 2.5µM 
RNAase inhibitor 0.2 µl 0.4U/µl 
RNA 1µl 1µg 
Multiscribe reverse 
transcriptase 
0.625µl 3.125U/µl 
RNAase free water 2.475µl - 
Total volume 10µl  
 
 
Table 2.6 Reverse transcription program cycle 
 
Stage Temperature Time 
1 25 oC 10 minutes 
2 37 oC 60 minutes 
3 48oC 30 minutes  
4 95oC 5 minutes 
 Hold at 10oC 
 
 
Table 2.7 CD248 and TBP PCR primers 
 
 
 
 
 
 
 
 
 
Table 2.8 PCR mix and program cycle 
 
Ingredient Volume Concentration 
10x buffer 5µl 1x 
dNTP 5µl 2mM 
cDNA 1µl 1µg 
Taq 1.5 µl 7.5U 
Forward primer  1µl 3.125mM 
Reverse primer 1µl 3.125mM 
RNAase free water 36.5µl - 
Total volume 50µl - 
  
 
Stage Temperature Time 
Initial denaturation  95 oC 3 minutes 
Denaturation  95 oC 30 seconds 
Annealing  61oC 30 seconds  
Extension 72oC 1 minute 
Final extension 72oC 10 minutes 
 Hold at 10oC  
50 cycles 
Target Sequence 
CD248 forward TTTGGCTTCGAGGGCGCCTG 
CD248reverse TCACACTGCTGCTCGCACGG 
TBP forward AACTTCGCTTCCGCTGGCCC 
TBP Reverse GCTGTGGTGCCTGGCCTGAG 
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2.1.9 Western blotting 
Recipes for the solutions and gels prepared for Western blotting are detailed in 
Tables 2.9 and 2.10. 
Table 2.9 Solutions for Western blotting 
Solution Ingredient Quantity Source 
10% Ammonium persulphate 
(APS) 
Ammonium persulphate 100mg Sigma 
Distilled water 1ml Sigma 
10x Tris buffered saline 
(pH  to 7.6 with pure HCL) 
Tris HCL 24.2g Sigma 
Sodum chloride 80g Sigma 
Distilled water Make up 
to 1litre 
Sigma 
Tris buffered saline-tween 20 10x Tris buffered saline 100ml Sigma 
Tween 20 1ml Sigma 
Distilled water Make up 
to 1litre 
Sigma 
Transfer buffer Glycine 2.93g VWR 
Tris-base 8.51g Sigma 
Sodium dodecyl sulfate 0.375g Sigma 
Methanol 200ml VWR 
Distilled water Make up 
to 1litre 
Sigma 
Running buffer Glycine 14.2g VWR 
Tris-base 3g Sigma 
Sodium dodecyl sulfate 100mg Sigma 
Distilled water Make up 
to 1litre 
Sigma 
6x loading buffer 1 M Tris-HCL 3.5ml Sigma 
Sodium dodecyl sulfate 1.28g Sigma 
75% glycerol 4.8ml Sigma 
β-mercaptoethanol 0.5ml Sigma 
Bromophenol blue 100mg Sigma 
Distilled water Make up 
to 10ml 
Sigma 
1.5 M Tris HCL  
(pH  to 8.8 with pure NaOH) 
Tris HCL 236.64g Sigma 
Distilled water Make up 
to 1litre 
Sigma 
0.5 M Tris HCL  
(pH  to 6.8 with pure NaOH) 
Tris HCL 78.78g Sigma 
Distilled water Make up 
to 1litre 
Sigma 
Coomassie stain Methanol 400ml VWR 
Distilled water 500ml Sigma 
Acetic acid 100ml Sigma 
Brilliant blue dye 1 g Sigma 
Destain Distilled water 500ml Sigma 
Methanol 400ml Sigma 
Acetic acid 100ml Sigma 
"
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Table 2.10 Non-denaturing gels 
Ingredient Resolving (10%) Stacking (10%) 
Protogel 
Acrylamide/Bis-acrylamide (30:1) 
(Geneflow, UK) 
3.33ml 1.3ml 
TrisHCl pH8.8 2.5 ml - 
Tris HCL pH6.8 - 2.5 ml 
10% APS 100µl 100µl 
Tetramethylethylenediamine 10µl 10µl 
Distilled water 4 ml 6.2ml 
Final volume 10 ml 10 ml 
 
Cells were lysed in CellLyticMT sample buffer. Protein content was quantified using 
the method of Bradford (284) using a commercial kit (BioRad). Equivalent amounts of 
protein were run on a 10% w/v non-denaturing SDS-PAGE gel. Gels were wet 
transferred onto polyvinylidenedifluoride (PVDF) membrane for 90 minutes at 80 
volts, blocked with 5% BSA in tris-buffered saline containing Tween 20 (TBS-T) and 
incubated with the primary antibodies at 4oC overnight followed by horseradish 
peroxidase-conjugated secondary for 1 hour at room temperature  (Amersham, 
Buckinghamshire, UK). Immunodetection was carried out using the ECL Kit 
(Amersham, Buckinghamshire, UK) according to the manufacturers protocol followed 
by exposure to X-ray film for 15 minutes. 
 
2.1.10  Patient samples 
Following local ethical approval (NRES 07/Q2602/42) I identified patients who 
underwent a percutaneous renal biopsy at the University Hospital Birmingham NHS 
Foundation Trust for the investigation of renal disease between June 1998 and 
November 2009. A prevalent cohort of 93 patients with a histological diagnosis of IgA 
nephropathy, who also had archived formal saline fixed paraffin tissue, was used for 
the study. Clinical and demographic data was collected from patient records. Normal 
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tissue sections were derived from nephrectomy samples taken during the course of 
routine clinical care for malignant disease and were also purchased commercially 
(Abcam). 
 
2.1.11  Immunohistochemistry 
Immunohistochemistry was performed on 4µm tissue sections cut onto glass slides 
from paraffin blocks. Sections were dewaxed in xylene and re-hydrated through a 
series of graded alcohols to water. Antigen retrieval was performed using Dako 
Target Antigen Retrieval solution in a waterbath at 95oC for 30 minutes. Sections 
were stained according to the Dako Envision-HRP kit protocol. Primary antibody was 
applied overnight at 4oC. An isotype control was substituted for primary antibody on 
serial sections. Sections were either counterstained with Mayer’s haematoxylin or left 
unstained for quantitative analysis. To allow confocal microscopy the same technique 
was followed but fluorescently labelled secondary antibodies were substituted for the 
Envision kit. Similarly, DAPI (Invitrogen) was substituted for Mayer’s haematoxylin. 
Slides were visualised using a Zeiss confocal LSM 510 microscope. 
 
2.1.12  Digital image analysis 
An interactive image analysis system was used for blinded assessment of interstitial 
CD248+ fibroblast numbers. Our group has previously found this to be a reliable 
method for the analysis of renal tissue sections (31, 32). The sections were blinded 
to the operator and stained for CD248. They were visualised at a magnification of 
x200. Images were captured using a Nikon Eclipse E400 microscope with a digital 
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imaging system controlled by NIS Elements software version 3.0 (Nikon).  Images 
were stored as TIFF files and imported into Aequitas IA image analysis software 
(DynamicData Links) where the digitalised image was converted to a two-colour 
scale image. Using the threshold function the image was processed so that positive 
staining was represented by yellow pixels measured as a percentage of the area of 
total image analysed. Sections with excessive background staining that made it 
impossible to digitally differentiate specific staining were excluded from analysis. For 
each patient the mean measurement of interstitial CD248 staining of 5 randomly 
selected non-confluent microscopic fields was determined. Blood vessel and 
glomerular staining was identified by the operator and excluded from the analysis 
using the computer software. 
 
2.1.13  Quantification of chronic damage 
The extent of chronic tissue damage within each biopsy specimen was assessed 
using the index of chronic damage (ICD), an established and rigorous predictor of 
renal outcome previously developed by our group (42). For each biopsy, one section 
was stained by periodic acid-methenamine silver and was examined by a consultant 
histopathologist (Professor AJ Howie, UCL, London, UK). 
 
2.1.14  Statistical analysis 
Linear regression analyses were performed to determine correlations between 
normally distributed data variables. Variables determined to not follow a Gaussian 
distribution by normality testing for skewness were normalised by transformation prior 
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to analysis. Correlations are presented by expressing the Beta correlation coefficient 
along with the P-value. Linear regression multivariate analysis of these correlations 
with a dependent variable was also performed. Renal outcome was assessed by 
Kaplan-Meier survival analysis with log rank testing and multivariate Cox regression 
analysis after categorisation of tubulointerstitial CD248, urinary ACR and the index of 
chronic damage into tertiles.  All statistical tests were performed using SPSS v17 
(IBM) and graphs were prepared using Prism 4 (GraphPad, USA). The level of 
significance was set at p<0.05. 
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2.2 Methods for Chapter 4 and 5: Murine studies 
2.2.1 Antibodies used for murine studies 
The primary, secondary and isotype control antibodies used for the murine studies 
described are detailed in Tables 2.11, 2.12 and 2.13. 
Table  2.11 Isotype controls 
 
Isotype Format Source 
Rat IgG2a ebioscience Appropriate to primary antibody 
Rat IgG2b ebioscience Appropriate to primary antibody 
Mouse IgG2a Dako Appropriate to primary antibody 
Polyclonal rabbit R&D Systems Appropriate to primary antibody 
 
 
Table  2.12 Anti-mouse primary antibodies 
 
Specificity Isotype clone Supplier Working 
dilution 
CD248 polyclonal rabbit polyclonal In house WB 1:3000 IHC 1:100 
Bovine serum albumin polyclonal rabbit polyclonal Invitrogen 1:1000 
αSMA mouse IgG2a 1A4 Sigma 1:50 
CD31 hamster IgG 2H8 Serotec 1:100 
E-cadherin rat IgG1 - Abcam 1:100 
CD3 polyclonal rabbit polyclonal Abcam 1:100 
F4/80 rat IgG2b A3-1 Serotec 1:100 
Gp38 (podoplanin) Syrian hamster IgG ebio8.1.1 ebioscience 1:100 
Synaptopodin mouse IgG1 G1D4 Progen neat 
GAPDH polyclonal rabbit polyclonal Abcam 1:2500 
BrdU mouse IgG1 B44 BD Biosciences 1:100 
CD45 rat IgG2b  30-F11 ebioscience 1:100 
PDGFRβ  rat IgG2a APB5 ebioscience 1:100 
 
 
Table 2.13 Anti-mouse secondary antibodies 
 
Specificity Conjugate Host Supplier Working 
dilution 
Anti-mouse IgG1 Alexa 488 goat Invitrogen 1:100 
Anti-mouse IgG2a Alexa555 goat Invitrogen 1:100 
Anti-hamster IgG Cy3 goat Jackson 1:100 
Anti-rat IgG Cy5 goat Jackson 1:100 
Anti-rat IgG Alexa 488 goat Invitrogen 1:200 
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2.2.2 Mice 
129SvEv mice were purchased from a commercial breeder and used to establish a 
colony (Taconic, Denmark). Mice were maintained in 12 hour light/12 hour dark cycle 
with free access to food and water. All procedures were performed in accordance 
with UK Home Office guidelines. Generation of CD248-/- mice by targeted 
homologous recombination, was performed by Professor David Huso’s group (John 
Hopkins University, USA)(271). These animals were backcrossed onto a 129SvEV 
background by Professor Clare Isacke (Breakthrough Breast Cancer, London, UK). 
This strain of mice was chosen due to its availability and susceptibility to develop 
renal disease following injury. Adult (>8 weeks old) male mice were used for all 
experiments.  As control, age and sex matched animals were used. Unless otherwise 
stated all in vivo studies had six mice in each experimental group. 
 
2.2.3 Genotyping of CD248-/- mice 
Genomic DNA was isolated from ear clippings of newborn mice. DNA was extracted 
using a DNAeasy Tissue Kit (Qiagen) as per the manufacturer’s instructions. Mice 
were genotyped using primers (table 2.14) designed to distinguish WT and CD248-/- 
genotype as previously described (271). The mix and programme used for PCR is 
detailed in Table 2.15. Samples were run on either a 0.5%, or a 1% agarose gel 
containing ethidium bromide at 130 volts and visualised under UV light. The 
presence of the wild type CD248 gene was denoted by a 1507bp fragment and the 
recombinant, disrupted CD248 gene by a 3000bp fragment; heterozygous animals 
displayed both bands (3000bp and 1507bp) (Figure 2.1). 
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Figure 2.1 
Genotyping of wildtype (WT) and CD248-/- mice (KO).  
 
The presence of the wild type CD248 gene was denoted by a 1507bp fragment (a) and the recombinant, CD248 
disrupted gene by a 3000bp fragment (b). 
 
 
 
 
Table 2.14 CD248 and TBP PCR primers 
 
 
 
 
 
 
Table 2.15 PCR mix and program cycle 
Ingredient Volume 
Reddy Mix PCR Master Mix (1.1X) 
(Thermo scientific) 
25"l 
Forward Primer (10pmoles/!l) 2"l 
Reverse Primer (10pmoles/!l) 2"l 
RNAase free water 16µl 
DNA  5"l 
Total for 1 reaction 50"l 
  
Wildtype program 30 cycles  
Stage Temperature Time 
Initial denaturation  95 oC 2 minutes 
Denaturation  95 oC 30 seconds  
Annealing  61.3oC 30 seconds  
Extension 72oC 160 seconds 
Final extension 72oC 5 minutes 
 Hold at 4oC  
 
CD248-/- program- 30 cycles 
Stage Temperature Time 
Initial denaturation  95 oC 2 minutes 
Denaturation  95 oC 30 seconds  
Annealing  62.4oC 30 seconds  
Extension 72oC 300 seconds 
Final extension 72oC 10 minutes 
 Hold at 4oC  
Target Sequence 
CD248-/- forward 5’- CTTGTGTAGCGCCAAGTGCC-3’ 
CD248-/- reverse 5’-GCTGGGAAGGATCTGGCAGG-3’ 
Wildtype forward 5’- CCTGGTTTCCAGCGAGTTCG-3’ 
Wildtype reverse 5’- GCCTGCAAGACCTGACTCTG -3’ 
$+",-,./0"
$+",-,./0"
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2.2.4 Tissue collection 
Animals were first weighed and then culled by cervical dislocation and rapidly 
perfused post-mortem with PBS. Both the kidneys were then removed and weighed. 
Samples were either fixed in 10% formal saline for histology or snap frozen in liquid 
nitrogen. 
 
2.2.5 Renal function 
Baseline urinary protein loss was determined in wildtype and CD248-/- mice by 
placing them in metabolic cages for 24 hours with free access to food and water 
(n=10). Urinary albumin and creatinine was measured using an AlbuwellM (Exocell) 
and creatinine companion kit (Exocell) respectively as per the manufacturer’s 
instructions. The ACR was then calculated. Blood was obtained by cardiac puncture, 
allowed to clot for 1 hour at 4oC then centrifuged at 10 000 rpm for 10 minutes, 
plasma was removed, transferred to a sterile 1.5 ml eppendorf and snap frozen in 
liquid nitrogen. Samples were then and sent to MRC Harwell (Oxford, UK) on dry ice 
for biochemical analysis. 
 
2.2.6 Histology 
The Queen Elizabeth Hospital Birmingham Pathology Department prepared paraffin 
tissue blocks from tissue fixed in 10% formal saline. Tissue sections (4µm) were cut 
onto glass slides. The pathology department then stained the sections, using 
haematoxylin and eosin, periodic acid silver or Masson’s trichrome. Slides were 
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visualised on a Nikon Eclipse E400 microscope with a digital imaging system 
controlled by NIS Elements Version 3.0 (Nikon).  Slides prepared from the same 
paraffin blocks were also used for immunoenzyme histochemistry as described 
above in section 2.1.11. 
 
2.2.7 Confocal microscopy 
Frozen sections (4µm) were prepared using a cryostat from kidney tissue snap 
frozen in liquid nitrogen. Sections were fixed by immersion in acetone for 20 minutes 
at 4oC. Following fixation sections were allowed to air dry at room temperature for 1 
hour and then stored at -20oC or were used immediately.  Tissue sections were 
stained as described in section 2.1.11 (human immunocytochemistry) 
 
2.2.8 In vitro functional analysis of cells from wildtype and CD248-/- mice 
2.2.8.1 Embryonic fibroblasts 
Mouse embryonic fibroblasts (MEF) were isolated from E14 and E15 embryos from 
wildtype and CD248-/- mice (a gift from Dr Debbie Hardie). Internal organs including 
the liver, heart, lungs, digestive tract, kidneys, thymus and lymph nodes were 
removed from decapitated bodies. The body shell was mashed in 1 ml of PBS, 
vortexed and 1ml of 1:1 10x Trypsin (5%) /EDTA (2%) (Sigma) in PBS and incubated 
at 37oC for 30 minutes. Digestion was stopped by the addition of 3.5ml RPMI 
containing 10% FCS. The cell suspension was centrifuged at 300 g for 5 minutes, re-
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suspended in 10mls of complete MEF media (Table 2.16) and placed into T25 flasks 
and cultured at 37oC in 5% CO2. 
 
2.2.8.2 Isolation of murine renal cell populations 
Renal cell populations were isolated from murine kidney using the Dynabead method 
of Takemoto et al (285) with adaptations. These 4.5 µm magnetic beads physically 
lodge in the glomerular blood vessels, the kidney can then be digested and the 
tubular and glomerular fractions separated using a magnet.  
 
Animals were culled by cervical dislocation and a midline laparotomy was performed 
to visualise the abdominal aorta. The vessel was ligated above and below the renal 
vessels using surgical microclips (Harvard Apparatus, Kent, UK) (Figure 2.2).   
 
 
Figure 2.2 
 
Renal perfusion with magnetic beads  
 
Renal cell populations were isolated from murine kidney. The vessel was ligated above and below the renal 
vessels. Magnetic beads inactivated in BSA were infused via a 30 gauge aortic cannula. 
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A 30-gauge cannula (Harvard apparatus, Kent, UK), was inserted and 4x105 of 4.5 
µm beads (Invitrogen M450, Dynal Biotech, UK) that had previously been blocked in 
10% BSA overnight, were infused using a syringe pump at a rate of 1ml/minute. The 
kidneys were then harvested, minced using two scalpels in a laminar flow cell culture 
hood and digested with 1 mg/ml collagenase A and 100 U/ml deoxyribonuclease I 
(Roche) diluted in Hanks buffered saline solution (HBSS) and incubated for 30 
minutes at 37oC. The digest was then passed through a 100µm sieve twice and 
washed with 10mls of HBSS. The cells were pelleted at 200g for 5 minutes at 4oC. 
The pellet was re-suspended in 10mls HBSS. The glomeruli were then separated 
from the tubules using a 15 ml falcon magnetic separator (Invitrogen).  The 
glomerular and tubular fractions were plated in media selective for either glomerular 
mesangial pericytes, tubulointerstitial fibroblasts or proximal tubular epithelial (see 
Table 2.16). 
 
2.2.8.3 Murine primary cell culture 
Cells were cultured, passaged, stored and characterised as described in section 
2.1.4 - 2.1.6. The media recipes used to culture primary murine cell lines are detailed 
in table 2.16. 
 
2.2.8.4 Wound healing assay 
Cells were seeded at 3 x105 cells per well into 6 well plates and cultured to 
confluence. Using a sterile 200 ml pipette tip a straight scratch was made in the 
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confluent cell monolayer. Phase contrast images were captured from the plate using 
an Olympus IX71 inverted microscope at 0, 6, 12 and 24 hours following monolayer 
injury. The microscope stage was marked using tape so that the plate could be 
returned to the same position every time an image was acquired. Image analysis was 
performed using NIH ImageJ.  Images were imported into ImageJ, the leading edge 
of the both sides of the wound was marked and measured and expressed as a 
percentage of the wound area at time 0. 
 
2.2.8.5 Proliferation 
Cell proliferation was assessed using an MTT (3- [4,5-dimethlythiazol-2-yl]-2,5 
diphenyltetrazo-lium bromide) based assay. Following 6 days incubation under 
treatment or control conditions the cell media was harvested and the cells incubated 
with a solution of MTT (20 µl of 5 mg/ml MTT in 100 µl un-supplemented media) and 
incubated at 37 oC for 4 hours. Viable cells reduce the MTT compound to a blue 
formazan product. There is a linear relationship between the number of cells and the 
amount of formazan product produced. MTT solution was poured off at the end of the 
incubation and after drying the cells were incubated with DMSO at 37 oC to dissolve 
the formazan crystals. The amount of product produced was then measured by a 
spectrophometer at 540nm.  
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Table 2.16  
Media recipes for murine primary cell lines 
 
Cell type Ingredient Volume Final concentration Source 
 
Mesangial cells 
Roswell park memorial institute 
(RPMI) 1640 medium 385ml - Gibco 
FCS 100ml 20% Sigma 
Gluatmine,penicillin, streptomycin 
(GPS) solution 
 
5ml 
1.75mM 
87U/ml 
87µg/ml 
Sigma 
HEPES 5ml 15mM Sigma 
Sodium Pyruvate 5ml 1mM Sigma 
 
Renal fibroblasts 
Dulbecco’s modified eagles 
medium/F12 (DMEM/F12) 445ml - Gibco 
FCS 50ml 10% Sigma 
Gluatmine,penicillin, streptomycin 
(GPS) solution 
 
5mls 
1.75mM 
87U/ml 
87µg/ml 
Sigma 
 
Proximal tubular  
epithelial cells 
(PTEC) 
DMEM/F12 395ml - Gibco 
FCS 2.5ml 0.5% Sigma 
Gluatmine,penicillin, streptomycin 
(GPS) solution 
 
5ml 
1.75mM 
87U/ml 
87µg/ml 
Sigma 
ITS solution 5ml 10µg/ml Insulin  
5.5µg/ml Transferrin  
5ng/ml Sodium 
selenite  
Sigma 
Endothelial growth factor (EGF) 50µl 1ng/ml Sigma 
Tri-idothyramie 1µl 5pg/ml Sigma 
Dexamethasone 1µl 5µg/ml Sigma 
Amphotericin 1ml 2.5µg/ml Sigma 
 
Mouse Embryonic 
Fibroblast  
(MEF) 
Dulbecco’s modified eagles 
medium/F12 (DMEM/F12) 395 ml - Gibco 
FCS 100ml 20% Sigma 
Gluatmine,penicillin, streptomycin 
(GPS) solution 
 
5mls 
1.75mM 
87U/ml 
87µg/ml 
Sigma 
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2.2.8.6 Collagen deposition 
A Picosirus red dye-binding assay originally described by Heng et al (286) was used 
for measuring collagen accumulation in vitro. Following a 6-day treatment period 
media was removed and the cell layers were washed in PBS. The cell layers were 
then fixed in Bouin’s solution for 1 hour at room temperature. The solution was then 
removed and plates washed in running tap water and air dried overnight. Sirius red 
dye solution (1 mg/ml in picric acid) was added to each well for 1 hour and placed 
under mild shaking. The dye solution was then removed and each well washed with 
0.01 N of hydrochloric acid to remove unbound dye. The bound dye in each well was 
eluted with 1 ml of 0.01N sodium hydroxide under mild shaking for 30 minutes. 
Optical density was then measured at 550nm using 0.1 N as a blank. Wells without 
cells treated identically were used as a background control.   
 
2.2.8.7 Crystal violet 
Crystal violet dye binding assay was used to determine the relative DNA content of 
each well. Cells were fixed in either 2% paraformalydehyde or Bouins solution 
(Sigma Aldrich, Poole, UK). Cell were rinsed with phosphate buffered saline and 
0.1% crystal violet dye solution was added to each well and placed under mild 
shaking for 30 minutes at room temperature. The unbound dye was removed by 
rinsing under running water. The plates were air-dried and bound dye eluted with 1% 
triton X-100. The elution was collected and absorbance at 550nm was determined 
using triton X-100 as a blank. Data were recorded as total absorbance units per well 
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and culture wells without cells were used as background control.  This assay was 
used to normalise the collagen deposition assay relative to total cell number. 
 
2.2.8.8 Stimulation with growth factors 
Cells were seeded at 50,000 cells per well in a 96-well plate in either differentiation 
media or normal growth media for 6 days. The media was changed every 2 days. 
Culture media was supplemented with either PDGF-BB at 100ng/ml or TGF-β1 at 10 
ng/ml and proliferation was compared to control conditions (un-supplemented 
media). Initial growth factor concentrations were decided on from the literature and 
through pilot studies using embryonic fibroblasts. 
 
2.2.9 Small animal models of renal fibrosis 
Two small animal models of renal disease previously described within the literature 
were piloted in Birmingham. A successful application was made to the United 
Kingdom Home Office for the award of a project licence and a personal licence under 
the Animals Scientific Procedure Act 1986 (Holder Stuart Smith PPL 40/3352, PIL 
40/9528). All experiments were performed at the Biomedical Services Unit (BMSU) at 
the University of Birmingham, UK. 
 
2.2.9.1 Protein overload model 
A bovine serum albumin nephrotoxicty model developed by Eddy et al (287) was 
used to induce renal fibrosis (Figure 2.3). Animals received injections of low 
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endotoxin BSA (Sigma Aldrich, Poole, UK,  A-9430) five times a week for a total of 6 
weeks. The BSA was dissolved in saline (0.33 mg/mL) and injected into the 
peritoneal cavity. The final dose of 10 mg BSA/g body weight was reached by 
incremental increases in the dose over the first week, beginning with 2mg/g body 
weight. All control animals received intra-peritoneal injections of an equal volume of 
saline on an identical schedule. Prior to sacrifice and tissue collection animals were 
placed in metabolic cages for 24 hours as described in section 2.2.5 to allow 
assessment of urinary protein loss. 
 
2.2.9.2 Unilateral Ureteric Obstruction 
Renal fibrosis was modelled using the established model of unilateral ureteric 
obstruction (UUO). Kidneys were harvested at days 3, 7 and 14 after UUO (Figure 
2.4). Using inhalational anaesthesia (4% Isofluorane, 2% oxygen) mice underwent a 
midline laparotomy; the left ureter was identified and ligated with an atraumatic 
micro-haemoclip (Weck) (Figure 2.5). Sham operated control mice underwent an 
identical procedure except the left ureter was mobilised but not ligated. Animals 
received a single subcutaneous dose of opiate based analgesia (Temgesic) at a 
dose of 0.05 mg/kg at the time of ligation. Following laparotomy animals were 
recovered and observed in a warming box for 24 hours. 
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Figure 2.3  
 
Outline of the protein overload model of renal fibrosis. 
 
Renal injury was induced using daily injections into the peritoneal cavity of low endotoxin bovine serum albumin 
for a total of 6 weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.4 
 
Unilateral ureteric obstruction model 
 
Renal fibrosis was induced using the established model of unilateral ureteric obstruction (UUO). Kidneys were 
harvested at days 3, 7 and 14 after induction of injury 
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Figure 2.5 
Surgical technique used to perform the UUO model.  
(A &B) Under inhalational anaesthesia mice underwent a midline laparotomy. (C) The abdominal contents was 
reflected and covered with gauze soaked in saline. (D&E) the left ureter was identified and ligated with an 
atraumatic micro-haemoclip. (F) The wound was repaired using sutures to the peritoneal cavity and skin clips. 
Clips were removed 7 days following the procedure.  
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2.2.10  Analysis of renal fibrosis in small animal models 
2.2.10.1 Tissue collection and analysis of renal function 
Tissue collection and analysis of renal function was performed as described in 
section 2.2.4-2.2.6. 
 
2.2.10.2 Sirius red staining 
Renal fibrosis was visualised and quantified with use of picosirius red staining. 
Twelve non-overlapping field at x400 magnification from each section were captured 
using a Nikon microscope and digital camera (Nikon, UK) with identical illumination 
and exposure. Digital image analysis was performed using Adobe Photoshop in a 
blinded manner. The colour range tool was used to threshold the images for positive 
staining. Threshold image settings were stored as a template and all images were 
analysed in batches with equivalent settings. The thresholded pixels were expressed 
as a percentage of the total pixels. This was taken to represent the percentage area 
staining positively for collagen. 
 
2.2.10.3 Immunohistochemistry 
Immunohistochemistry was performed on murine kidney sections cut from paraffin-
blocked tissue and frozen tissue sections as described in section 2.1.11. 
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2.2.10.4 Western blotting 
Western blotting to confirm protein expression in murine tissue was performed as 
described in section 2.1.9 with the substitution of appropriate primary and secondary 
antibodies. 
 
2.2.10.5 Real time polymerase chain reaction 
RNA was extracted from whole kidney homogenates and transcribed into cDNA as 
described in section 2.1.8. Quantitative polymerase chain reaction was performed on 
384 well plates using TaqMan Gene Expression assays; CD248 (Mm00547485), 
F4/80 (Mm00802529), CD3 (Mm00438095), α-SMA (Mm00725412), FSP-1 
(Mm00803372), Collagen 1A (Mm00801666), E-cadherin (Mm01247357), TGF β1 
(Mm00441726) and GAPDH (4352339E) was used as a housekeeping gene. Assays 
were run on a 7900HT Real Time PCR System (Applied Biosystems). 
 
Table  2.17 Quantitative PCR mix and program cycle 
Ingredient volume concentration 
cDNA 2µl 20ng/µl 
Primer 1µl x20 
Master mix 10µl x2 
dH20 7µl  
Total volume 20µl  
 
 
 
Stage temperature time 
1 50oC 2 minutes 
2 95oC 10 minutes 
3 95oC 15 seconds  
4 95oC 1 minute 
 Hold at 10oC 
40 cycles 
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The cycle number (Ct) for the target gene was subtracted from the Ct for the control 
gene and the relative quantity was calculated as 2-ΔCT. This was then normalised to a 
control sample and results expressed as mRNA fold change relative to control. 
 
2.2.10.6 Stromal cell subpopulations 
Fibroblast subpopulations were assessed using confocal microscopy as previously 
described by Zeisberg et al (108).  A Zeiss LSM 510 Meta scanning confocal 
microscope was used to capture ten visual fields per kidney at x630 magnification. 
These images were analysed for co-localization of stromal cell markers using cell 
counting.  
 
2.2.10.7 Myofibroblast cell counts 
Myofibroblasts were detected in tissue sections of the kidney from wildtype and 
CD248-/- mice following 14 days following UUO. Sections were co-labelled with DAPI 
and myofibroblasts were detected using an antibody directed towards α-smooth 
muscle actin. Quantification of the number of myofibroblasts (α-SMA positive cells) 
was performed by detection of CY-3 immunofluorescence (secondary antibody, red 
stained cells) using confocal microscopy. The percentage of α-SMA positive cells 
(positive CY-3 immunofluorescence) per high-powered field was quantified in 10 
cortical interstitial fields randomly selected at original magnification ×400. α-SMA+ 
cells were identified by greater than 75% of the cell area immediately surrounding 
nuclei (detected by DAPI) staining positive with Cy3 fluorescence indicative of the 
antigen expression. Blood vessels were excluded from the analysis. Results were 
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expressed as Mean +SEM of 10 fields of view per mouse tissue section with an n=6 
mice per group.  
 
2.2.10.8 Vascular studies 
For microvascular studies mouse tissue sections were stained with anti-CD31 
antibody as described above. Specific cells were counted in 10 cortical interstitial 
fields randomly selected at ×400 magnification per mouse tissue section. Vessel 
fluorescence was detected using CY-3 fluorescence and analysed in images at ×400 
magnification captured from CD31-stained sections of 10 different fields from six 
different animals. Quantification of the number of fluorescence pixels was calculated 
using Adobe Photoshop version 7. All images and analysis was performed using 
constant fluorescence intensity and standardised confocal settings. A Zeiss confocal 
LSM 510 microscope (Zeiss, Germany) was used to visualize staining with images 
captured and processed using the Zeiss LSM Image Examiner software (Zeiss). 
Representative images were chosen from each experiment for figure editing. 
 
The percentage area per field covered by vessels (positive CY-3 
immunofluorescence) was then expressed as a percentage of the total pixel count. 
For vascular length studies whole sections were imaged using the Leica LSI TCS 
Zoom confocal. The vessel length was calculated for all vessels within a randomly 
selected field of view (4 fields of view per tissue section in 4 animals per treatment 
group) with the exclusion of vessels crossing the boarder of the selected area. 
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Vessel length was expressed in mm and calculated using the ruler tool in the LAS AF 
version 2.3.5 software. 
 
2.2.10.9 In vivo Bromodeoxyuridine (BrdU) studies 
Mice were administered, via an intraperitonal injection, with 200µl of 
bromodeoxyuridine (BD Biosciences) diluted to a concentration of 10mg/ml in PBS. 
Animals were left for 48 hours before tissue was collected to allow the incorporation 
of BrdU into proliferating stroma. 
 
2.2.10.10 Bone marrow chimera 
Foetal liver cells were isolated from C57BL/6J mice expressing enhanced yellow 
fluorescent protein (eYFP) in all tissues under the control of the Rosa26 promoter 
and ubiquitin (gift from Professor Graham Anderson). E14 and E15 embryos were 
removed and transferred to a class II biological hood for dissection. The liver was 
identified, dissected and homogenised into a single cell suspension in RPMI using a 
1 ml pipette. The homogenate was then filtered through a 30µm sieve into a 15 ml 
falcon tube. Cell yield was assessed using a haemocytometer. Cells were stored in 
the dark on ice until needed. Thirty minutes prior to injection cells were centrifuged at 
400g for 5 minutes at 4 oC then re-suspended in 10mls of PBS and passed through a 
40µm filter. 
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Adult male C57BL/6J mice aged 8-14 weeks were purchased from Harlan 
laboratories. At least 1 week before irradiation and cell transfer, mice were given 
Baytril (Enrofloxacin). Mice were given lethal total body irradiation of 900 rads in two 
divided doses of 450 rads separated by 3 hours. One hour later they were 
reconstituted with 5 x106 fetal liver cells injected intravenously. Animals were left to 
reconstitute for 8-12 weeks. Only healthy mice with no signs of graft versus host 
disease were used in experiments. 
 
2.2.11  Statistical analysis 
Results are presented as means +/- SEM. The statistical significance of differences 
between means was assessed using one-way or two-way analysis of variance 
(ANOVA) with appropriate post-test analysis or two-tailed Student’s t-test. Values of 
P<0.05 were considered significant. Analysis and graphs were prepared using Prism 
4 (GraphPad, USA). 
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CHAPTER 3 
EXPRESSION OF CD248 IN HUMAN RENAL DISEASE 
3.1 Introduction 
CD248 is expressed on resident stromal cells of the kidney. Observations from 
human studies, using small numbers of samples, suggest that at basal levels in the 
adult kidney, CD248 is expressed in the glomerulus on specialised pericytes more 
commonly referred to as mesangial cells (266). Analysis of human malignant tissue 
has shown that in renal cell carcinoma (RCC) expression is significantly increased 
and large rafts of CD248 positive stromal fibroblasts can be seen within the 
interstitium (266). More recently the group of Huang et al have generated a knock in 
mouse where CD248 expression can be tracked using a LacZ reporter gene (270). 
These studies again confirm CD248 expression by mesangial pericytes of the 
glomerulus. 
 
Despite these reports a detailed analysis of CD248 expression in human kidney 
disease has not been performed. I therefore hypothesised that CD248 expression is 
increased in human kidney disease and that expression may provide a tool to predict 
disease outcome. Initially I reaffirmed and expanded on earlier observations from 
other groups (157, 163) concerning the expression of CD248 in normal renal tissue, 
before characterising CD248 expression in a large cohort of patients with progressive 
CKD. In situ CD248 expression was analysed against recognised determinants of 
renal disease progression and outcome, to assess the relevance of this molecule in 
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human kidney disease, both as a predictor of disease progression and as a 
candidate therapeutic target. 
 
3.2 Results 
3.2.1 Characterisation of CD248 expression in cultured human renal cells. 
Renal fibroblasts were isolated from the non-affected pole of human kidney samples 
removed for the treatment of malignant disease to allow the examination of CD248 
expression in vitro (Figure 3.1). CD248 was expressed by renal fibroblasts (n=3) but 
not by glomerular endothelial cells (GEC), podocytes (POD) or human umbilical vein 
endothelial cells (HUVEC). Cellular protein and RNA expression was confirmed by 
Western blotting and reverse transcription polymerase chain reaction respectively 
(Figure 3.2).  
 
 
 
3.2.2 Characterisation of CD248 expression within normal kidney. 
To examine CD248 expression in human renal stromal cells in vivo I performed 
immunohistochemistry on a control group of patients with archived tissue taken from 
the non-affected pole of nephrectomies performed for the treatment of malignant 
disease (n=22. 9 females, 11 males. Median age 65, range 39-85). All control 
patients had normal renal function (eGFR>90). These studies confirmed CD248 
expression within the glomerulus, localised to mesangial cells (Figure 3.3).  
Tubulointerstitial staining was scant and when present it was localised to the 
interstitial space. 
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Figure 3.1 
 
Isolation of renal fibroblasts from human nephrectomy tissue. 
 
Phase contrast and confocal microscopy images are shown. During the early stages of primary culture (Day 7, 
passage 2), fibroblast cultures were contaminated by cobblestone shaped proximal tubular epithelial cells (arrow). 
Passaging lead to the over growth by fibroblasts and by day 4 passage 4 all of the cultured cells displayed a 
mesenchymal pattern. These cells stained uniformly positive for the fibroblast marker vimentin but negative for 
CD31 (endothelial marker), desmin (mesangial cell marker) and cytokeratin (epithelial cell marker). 
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Figure 3.2 
CD248 expression by human renal fibroblasts in vitro 
Top: Confocal microscopy studies demonstrated CD248 (green) expression by renal fibroblasts (RF) but not by 
human umbilical vein endothelial cells (HUVEC), glomerular endothelial cells (GEC) or podocytes (POD), data not 
shown (n=3). Middle and bottom: RT-PCR and Western blotting confirmed the immunostaining pattern observed. 
Beta actin (β-Actin) and TATA binding protein (TBP) were used as positive controls. 
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3.2.3 CD248 expression and determinants of renal progression 
To investigate the potential role CD248 may play in the tissue remodelling that 
accompanies progressive CKD, I performed a detailed histological analysis of a 
cohort of patients with IgA nephropathy. IgA nephropathy was chosen as progression 
in these patients is known to be tightly linked to albuminuria and interstitial fibrosis at 
diagnosis (discussed in detail in Chapter 1)(46).  
 
One hundred patients with an adequate renal biopsy to make a diagnosis of IgA 
nephropathy were identified. Ninety-three had archived tissue and clinical data 
suitable for analysis (60 males and 33 females). Table 3.1 summarises the clinical, 
pathological and experimental characteristics analysed.  
 
Table 3.1  
Study population: Clinical, pathological and experimental characteristics (n=93). (See Chapter 1, section 
1.5.3.4 for a description of the index of chronic damage). 
 
 Median Range 
Age (years) 42 18-82 
eGFR (ml/min/1.73m2) 56 6-99 
ACR (mg/mmol) 60 0.8-1097 
Index of chronic damage (%) 17 0-94 
Tubulointerstitial CD248 (%) 6.8 1.42-31.57 
 
Histological analysis of the biopsy samples demonstrated diffuse tubulointerstitial 
staining for CD248 (Figure 3.3).  CD248 expression was also found to be increased 
in the mesangial cells of the glomerulus in inflamed kidney tissue (Figure 3.3f). 
Quantification of the interstitial staining using an interactive image analysis system 
showed expression to be greater in patients with more advanced disease. Previous 
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studies by our group (31, 32) have demonstrated a relationship between albuminuria, 
renal function, index of chronic damage and progressive CKD. I therefore analysed 
the relationship between these parameters and CD248 expression in situ in the 
cohort of 93 patients with IgA nephropathy. 
 
By univariate analysis; the urinary ACR correlated with tubulointerstitial expression of 
CD248 (correlation 0.500; P<0.0000) (Table 3.2; Figure 3.4). Estimated glomerular 
filtration rate (eGFR) inversely correlated with urinary ACR but not as strongly as 
tubulointerstitial CD248 expression (correlation -0.360; P=0.0004) (Table 3.2; Figure 
3.4)). Interstitial CD248 expression correlated with renal fibrosis as assessed by the 
index of chronic damage (correlation 0.539; P<0.0000), and eGFR (correlation -
0.679; P<0.0000) (Table 3.2; Figure 3.4)). These univariate correlations were 
maintained in a multivariate linear regression analysis of the variables. 
Tubulointerstitial CD248 expression, urinary ACR, index of chronic damage and 
eGFR were all interdependent variables (Table 3.3). Notably tubulointerstitial CD248 
expression independently associated with urinary ACR (0.299; p=0.002).  Again, as 
our group has previously published (31, 32) using other disease cohorts, classical 
determinants of CKD progression (for example, urinary ACR and eGFR) were 
interdependent. 
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Figure 3.3 
Immunohistochemistry for CD248.  
Normal human kidney (n=22). (a) x100 CD248 (Brown) localises to the vascular pole (arrow)  with weak 
expression seen in the mesangial cells of the glomerulus. There is scant expression in the tubulointerstitium on 
peri-tubular fibroblasts (*). (b) x400 glomerular expression of CD248. (c) In progressive CKD (n=93) there is 
diffuse expression of CD248 throughout the tubulointerstitium. Images shown are taken from a renal biopsy 
specimen from a patient with CKD stage IV. Shown at higher power in panel  d and e (arrow to CD248 staining).  
(f) magnification x630. Glomerular expression of CD248 was also increased in the mesangial cells of inflamed 
kidney.(g) magnification x100. Confocal microscopy to co-localise CD248 (green) and aSMA (red). Distinct 
subpopulations (**) can be seen and are described in more detail in figure 5. (h) CD248 (green) was not 
expressed by CD45 positive cells (red)(arrow). 
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Table 3.2 
Univariate correlations  
Univariate analysis of correlations between urinary ACR, tubulointerstitial CD248, index of chronic damage and 
eGFR (n=93) 
 Urinary ACR 
Correlation; P-value 
Tubulointerstitial 
CD248 
Correlation; P-value 
Index of  
chronic damage 
Correlation; P-value 
Urinary ACR NA   
Tubulointerstitial CD248 0.500; 0.0000*  NA   
Index of chronic damage 0.512;0.0000*  0.539;0.0000* NA  
eGFR -0.360;0.0004*  -0.515; 0.0000*  -0.679;0.0000*  
 
 
 
 
 
 
 
 
Table 3.3  
 
Multivariate linear regression analysis  
 
Multivariate linear regression analysis between urinary ACR, tubulointerstitial CD248, index of chronic damage 
and eGFR (n=93). 
 
      Dependent variable 
 Urinary ACR 
Beta; P-value 
Tubulointerstitial 
CD248 
Beta; P-value 
Index of  
chronic damage 
Beta; P-value 
eGFR 
Beta; P-value 
Urinary ACR NA  0.299;0.002*  0.253;0.003*  0.517;0.577  
Tubulointerstitial  CD248 0.329;0.002*  NA  0.150;0.097  -.225;0.019*  
Index of chronic damage 0.380;0.003*  0.204;0.097 NA  -0.584;0.000*  
eGFR 0.067;0.577  -0.268;0.019*  -0.510; 0.000*  NA  
ACR=albumin-creatinine ratio  NA=not applicable eGFR=estimated glomerular filtration rate 
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Figure 3.4 
Correlation of CD248 expression against determinants of renal progression 
Plots of correlation (correlation; P-value). (top) between ACR and tubulointerstitial CD248 staining (0.500; 
p<0.0000), between (middle), between Index of chronic damage and tubulointerstitial CD248 (0.539;p<0.0000) 
(bottom) eGFR and tubulointerstitial CD248 (-0.679; p<0.0000)  
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3.2.4 CD248 defines subpopulations of stromal cells  
Depletion of αSMA has previously proven detrimental to the progression of renal 
disease (125). I therefore wished to identify if CD248 was expressed by αSMA+ 
myofibroblasts to help determine if CD248 may represent a viable target for the 
treatment of CKD. Confocal microscopy was used to localise αSMA and CD248 in 
advanced IgA nephropathy (n=3). Again, CD248 was found to be localised to the 
tubulointerstitium. Immunofluorescence demonstrated 3 subsets of CD248+stromal 
cells: CD248+αSMA-, CD248+αSMA+ and CD248-αSMA+ (Figure 3.5). CD248 did not 
co-localise with the leukocyte marker CD45 (Figure 3.3). 
Figure  3.5 
Confocal  microscopy of human IgA nephropathy renal biopsy samples 
Confocal  microscopy of human renal biopsy samples from patients with CKD 3 and 4 (n=3) were stained to co-
localise αSMA (red) and CD248 (green). Nuclei are shown in blue. CD248+αSMA- , CD248+αSMA+ and CD248-
αSMA+ subpopulations can be seen in all biopsy samples and specific cell populations are highlighted in each 
panel.  Panel (a) CD248+αSMA- (arrows). Panel (b) CD248-αSMA+ (arrows).Panel (c) CD248+αSMA+ (arrows). 
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3.2.5 Renal survival 
To assess if CD248 expression is an independent predictor of renal survival I 
reviewed the renal outcomes of my patient cohort. Data on renal outcome was 
available for all ninety-three patients studied. Patients were followed for up to 1095 
days following renal biopsy.  Nineteen patients reached a renal end-point (7 patients 
doubled their serum creatinine; 12 patients reached ESRF) after a mean period of 
285 days (range 1-975 days; one patient commenced dialysis at day 1). Kaplan 
Meier survival analysis demonstrated that patients with extensive tubulointerstitial 
staining for CD248, particularly tubulointerstitial CD248>9.8%, was predictive of 
poorer renal outcome (Log rank testing for equality of survivor function statistic 
χ 2=18.28, P=0.0001). Similar predictive outcomes were seen for albuminuria 
(χ2=25.72, P=0.0001) and index of chronic damage (χ 2=31.74, P=0.0001) (Figure 
3.6). Therefore univariate and multivariate analysis of these variables was performed. 
This demonstrated CD248 to be an independent predictor of renal survival in our 
cohort (Table 3.4).   
 
Table 3.4  
Univariate and multivariate analysis of renal survival 
 Urinary  
ACR 
Exp(B); 
P-value; 
95% CI 
Tubulointerstitial 
CD248 
Exp(B); 
P-value; 
95% CI 
Index  
of chronic  
damage 
Exp(B); 
P-value; 
95% CI 
Age 
Exp(B); 
P-value; 
95% CI 
Sex 
Exp(B); 
P-value; 
95% CI 
eGFR 
Exp(B); 
P-value; 
95% CI 
Univariate 
2.120; 
<0.0001 
1.428-3.146 
44.997; 
<0.0001 
7.649-264.712 
1.666; 
<0.0001 
1.324-2.096 
1.008; 
0.561 
0.982-1.034 
1.113; 
0.821 
0.438-2.82 
0.935; 
<0.0001 
0.908-0.963 
Multivariate NS 12.09; 0.008; 1.89-77.39 NS 
0.968; 
0.008 
0.942-0.995 
NS 
0.934; 
<0.0001 
0.905-0.964 
NS=Not significant 
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Figure 3.6    
Kaplan-Meier survival analysis     
(Top) Effect of urinary ACR on renal outcome.(%2=25.72, P=0.0001). (Middle) Effect of the index of chronic 
damage on renal outcome.(%2=31.74, P=0.0001).  (Bottom) Effect of tubulointerstitial expression of CD248 on 
renal outcome.(%2= 18.28, P=0.0001) 
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3.3 Discussion 
This chapter characterises the expression of the stromal cell marker CD248 in normal 
kidney and in the kidney tissue of a cohort of patients with progressive renal disease. 
IgA nephropathy was chosen as a model of progressive human CKD because 
classical determinants of renal progression are recognised to be important in 
determining long-term renal survival in these patients (31, 140). CD248 has 
previously been demonstrated to be expressed on fibroblasts and pericytes found 
within inflammatory stroma (266). 
 
The in-house anti-CD248 antibodies used here have been extensively characterised 
in the literature both in vitro (163, 164) and in vivo (157, 165) to recognise fibroblasts 
and pericytes and the studies presented here are further confirmation of this 
specificity. Importantly they do not recognise endothelial cells or leucocytes(165). 
Although in humans a population CD8+CD45+ T cells and also a population of 
vascular leukocytes have been reported (248, 249), importantly no CD248+CD45+ 
cells were seen in my studies. 
 
In vitro and in vivo studies have shown that in healthy non-inflamed kidney that 
CD248 is expressed by resident pericytes and on stromal fibroblasts. In injured 
human fibrotic kidney tissue, CD248 is increased and expressed on a subpopulation 
of myofibroblasts (CD248+αSMA+) in addition to a population of CD248+αSMA- 
stromal fibroblasts. CD248-αSMA+ myofibroblasts were also seen. I was unable to 
phenotype these cells further using the tissue samples that were available. This is 
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the first description of a novel myofibroblast population that is CD248+αSMA+ and 
also of a population of CD248+αSMA- fibroblasts.   
 
The origin and heterogeneity of renal stromal myofibroblasts is diverse and 
recruitment may occur either from the resident cell populations, from circulating bone 
marrow derived precursors or through the process of EMT(5). Zeisberg et al have 
demonstrated, using lineage tracing techniques in mice, that EndMT may also 
contribute to the fibroblast populations observed in renal disease. They demonstrated 
that 30-50% of fibroblasts seen in an animal model of renal fibrosis co-expressed the 
endothelial cell marker CD31 and both fibroblast and myofibroblast surface markers 
(108). Here I have identified a novel subset of CD248+αSMA+ myofibroblasts and 
also a population of CD248+αSMA- fibroblasts thus emphasising the heterogeneity of 
the fibroblast and myofibroblast populations found in CKD.  Furthermore,  αSMA- 
fibroblasts are described in the renal literature and are known to contain and express 
interstitial collagens in vivo (118). Fibroblasts isolated from αSMA null mice produce 
more type collagen 1 compared to wildtype controls(125). 
 
Studies by Lin et al have highlighted the importance of the renal pericyte and of injury 
to the vasculature in driving fibrosis (51). Their observations in murine models of 
renal injury are supported further by the identification of CD248 expression by 
resident renal pericytes in close approximation to the vasculature; and the 
accompanying upregulation of CD248 in human disease. However, the studies 
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described here fall short of demonstrating categorically that in progressive human 
renal disease, CD248+ cells, or a sub-population thereof, are derived from pericytes. 
 
The extent of tubulointerstitial fibrosis seen at kidney biopsy has been repeatedly 
demonstrated to be a rigorous predictor of renal progression (14, 31) and my data is 
the latest confirmation of this long known association. The current studies do not, 
however demonstrate that a causal role is played by CD248 in progressive renal 
scarring, but the close association with albuminuria and renal scarring which are 
known determinants of renal disease progression and also the association between 
CD248 and renal survival outcomes is intriguing. Importantly this relationship was 
maintained in a multivariate analysis. 
 
In conclusion, in this chapter I have demonstrated that the stromal fibroblast and 
pericyte marker CD248 is upregulated in chronic kidney disease and that this is 
linked to known determinants of renal progression. The expression of CD248 on 
stromal fibroblasts and pericytes is already robustly established in the literature. 
However, here I report the additional observation that CD248 defines a 
subpopulation of myofibroblasts and also a subpopulation of CD248+αSMA- 
fibroblasts that are linked to albuminuria and tubulointerstitial damage, suggesting 
that CD248 may be implicated in the tissue remodelling seen in CKD. 
Immunostaining  for CD248 positive cells may not only provide a valuable histological 
guide to predict  renal progression but also raises the possibility that  CD248 positive 
stromal cells may be a potential target for the modulation of renal disease using 
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novel anti-angiogenic drugs such as the anti-human CD248 monoclonal antibody 
MORAb-004. 
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CHAPTER 4 
MURINE RENAL EXPRESSION AND IN VITRO FUNCTION OF CD248 
4.1 Introduction 
In Chapter three I described how renal biopsy samples were used to characterise the 
stromal cell expression of CD248 in healthy and diseased human tissue. In situ 
expression of CD248 increased in biopsy specimens taken from patients with 
progressive renal disease. CD248 expression was found to be linked to known 
determinants of renal disease progression. Furthermore, histological assessment of 
renal biopsy samples for CD248 expression was a predictor of renal disease 
outcome. These studies did not, however, demonstrate a definitive causal role for 
CD248 in the development of renal fibrosis. To investigate the potential for this I have 
used transgenic mice in which CD248 has been constitutively removed (CD248-/- 
mice) to look for functional defects in cells and tissue that might evidence a role for 
CD248 in the development of renal fibrosis. 
 
In this chapter the expression of CD248 in resting murine kidney will be described 
and the in vivo structure and function of healthy kidney tissue taken from CD248-/- 
animals assessed. In vitro studies using cells isolated from wildtype and CD248-/- 
animals have been performed to try and identify functional defects in stromal cells 
isolated from CD248-/- animals. I found that murine CD248 expression patterns 
appear similar to those observed in the human kidney and that CD248-/- mice have 
normal renal structure and function. Stromal pericytes and fibroblasts, but not 
epithelial cells, isolated from CD248-/- mice exhibit functional defects in vitro that 
109"
"
suggest these animals may be protected against the development of fibrosis 
following renal injury. 
 
4.2 Results 
4.2.1 Expression of CD248 in normal murine kidney 
Expression of CD248 during renal development was examined in wildtype mice. 
Tissue was removed from mice at embryonic day 16 (E16), postnatal day 2 (p2) and 
at 2, 4, 6, 8 and 10 weeks of age. Immunohistochemistry was used to localise CD248 
expression in paraffin-embedded tissue sections (Figure 4.1). At E16 it was not 
possible to remove the kidneys due to their size; therefore whole embryos were fixed, 
sectioned and stained. CD248 expression was high in the embryonic kidney (E16) 
where it was diffusely expressed in the developing tubulointerstitial space and 
glomerulus, expression remained high postnatally at postpartum day 2 (p2). 
Expression decreased during the course of postnatal development and by adulthood 
(week 6) expression was observed in mesangial cells of the glomerulus and on a 
scattered population of peri-tubular cells. No difference in expression could be 
identified between weeks 6 and 10. Co-localisation studies to confirm mesangial 
pericyte expression of CD248 were performed on frozen adult murine kidney tissue 
(Figure 4.2). CD248 was expressed by mesangial pericytes (PDGFRβ+) of the 
glomerulus, but not by glomerular endothelial cells (CD31+) or podocytes 
(Synaptopodin+). In the tubulointerstitium CD248 was seen on a population of peri-
tubular cells that morphologically appeared to represent pericytes. These CD248+ 
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stromal cells had long processes that wrapped around peri-tubular blood vessels but 
were themselves CD31-  (Figure 4.2, m-o). 
 
Figure 4.1  
Temporal and developmental expression of CD248 
Paraffin sections of murine tissue from 129SvEv animals. In common with most pericyte markers CD248 (brown), 
is temporally regulated during development. (n=3) 
(A) Embryonic day 16 (E16) x40 magnification.  CD248 is expressed throughout the developing tubulointerstitium 
and within early mesangial pericytes of developing glomeruli.  
(B, C&D) High power magnification of panel A. (E) At postpartum day 2 CD248 expression is downregulated in 
the kidney, x40 magnification.  
(F&G) Adult murine tissue, x100 & 200 magnification. CD248 expression is low and limited to mesangial pericytes 
of the glomerulus and peri-tubular cells (panel G, **) 
 
 
 
 
 
111"
"
Figure  4.2  
In normal, non-inflamed kidney CD248 is expressed by resident renal pericytes. 
Analysis of adult murine tissue using confocal microscopy (n=3). 
(a,c,&d) CD248 (blue) localises to mesangial pericytes of the glomerulus identified by PDGFRβ (panel a green 
and panel d at the arrow showing as cyan) 
(b&f).  CD248 (blue) does not co-localise with CD31 positive endothelial cells (red)  
(g&e) CD248 (blue) does not co-localise with podocytes identified with synaptopodin (blue)  
(d&h) show composite images. 
(i, j&k) Tubulointerstitial expression of CD248. CD248 (blue) is expressed by pericytes wrapped around peri-
tubular blood vessels. E-cadherin (green) identifies tubular epithelial cells.  
(l,m,n&o) Merged image shown in l and zoomed images in m,n & o. CD31(red) (arrow panel n) positive 
endothelial cells within the tubulointerstitium are supported by CD248 positive pericytes (blue) (arrow panel m).  
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4.2.2 Renal phenotype of CD248-/- mice 
The baseline renal phenotype of CD248-/- mice was characterised compared to 
wildtype control animals. Histological examination of the tubulointerstitial and 
glomerular compartments revealed no difference between wildtype and CD248-/- 
animals (n=10) (Figure 4.3 A and B).  Furthermore, there was no significant 
difference in body weight, urinary protein loss or renal function between the two 
groups (student t-test P>0.05, ns, n=10) (Figure 4.3 C-F).  
 
 
Figure 4.3 
 
Wildtype and CD248-/- mice have identical renal function and architecture.  
 
(A) Haematoxylin and eosin and (B) periodic acid silver staining of kidney tissue from adult mice. Wildtype and 
CD248-/- mice had normal glomerular and tubulointerstitial structure. No significant difference (student t-test 
P>0.05, ns, n=10) in body weight(C), Urinary albumin creatinine ratio (D), serum creatinine (E) or blood urea 
nitrogen levels (F) were observed in wildtype and CD248-/- mice (n=10).  
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4.2.3 In vitro functional studies 
To assess a potential functional role for CD248 expression on stromal cells, in vitro 
assays to measure cell proliferation and collagen deposition were performed. CD248 
expression is high during murine development and therefore plate-based assays 
were first optimised on embryonic fibroblasts isolated from wildtype and CD248-/- 
animals. 
 
Cells were treated with growth factors to assess their responses. PDGF-BB was 
chosen as it has previously been implicated in CD248 signalling pathways (166). 
TGFβ1 was chosen as expression is upregulated in fibrotic tissue and this growth 
factor is well recognised to participate in stromal cell activation in response to injury. 
Murine embryonic fibroblasts (MEFs) were seeded into 96 well plates to assess 
proliferation and collagen deposition. A time course and growth factor dosing study 
was first performed on cells isolated from wildtype animals (Figure 4.4).  
 
Maximal cellular proliferation and collagen deposition was observed by day 6 
following seeding (Figure 4.4). This time point was therefore used for all subsequent 
studies. In response to PDGF-BB, wildtype MEF proliferated and deposited collagen. 
A concentration of 100 ng/ml of PDGF-BB induced a significant response compared 
to control; this concentration of growth factor was therefore used in all subsequent 
experiments, and is a comparable concentration to that used by other studies found 
within the literature. Similarly, in response to stimulation with TGFβ1, the proliferation 
of wildtype MEF was reduced and collagen deposition increased (Figure 4.4). A 
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concentration of 10 ng/ml was found to induce a significant response compared to 
control and this dose was therefore used in subsequent experiments. 
 
Having established the optimal time point and growth factor concentration to 
stimulate wildtype MEFs, CD248-/- MEFs were then assessed. Preliminary studies 
demonstrated a significant reduction in the proliferative capacity and the amount of 
collagen deposited by CD248-/- MEFs compared to wildtype MEFs (Figure 4.5). Thus 
to accurately assess collagen deposition following stimulation with PDGF-BB and 
TGF-β1, cell number was quantified using a crystal violet assay and collagen 
deposition corrected for total cell number. 
 
In response to stimulation with PDGF-BB (Figure 4.5) wildtype MEFs demonstrated a 
significant increase in proliferation relative to control. In contrast CD248-/- MEFs failed 
to proliferate. In response to TGF-β1 wildtype and CD248-/- MEFs both demonstrated 
a reduced proliferative response. In contrast, in response to TGFβ1 CD248-/-  MEFs 
failed to deposit collagen but wildtype MEFs deposited large amounts of matrix. This 
trend in collagen deposition was also seen in response to stimulation with PDGF-BB 
but to a lesser extent. 
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Figure 4.4 
Wildtype MEFs time course and growth factor dose titration 
(A) Proliferation studies. (B) Collagen deposition studies.  
Maximal cellular proliferation and collagen deposition was observed by day 6 following seeding.  
In response to PDGF-BB, wildtype MEFs proliferated and deposited collagen. A concentration of 100 ng/ml of 
PDGF-BB induced a significant response compared to control. In response to stimulation with TGF!1, the 
proliferation of wildtype MEF was reduced and collagen deposition increased.  A concentration of 10 ng/ml was 
found to induce a significant response compared to control. Growth factor titration studies (middle and far right 
panels) show data collected at day 6 of treatment. (One-Way ANOVA with Bonferroni post-test, n=3 *p=<0.05, 
**p<0.001, ***p=<0.0001).  
"
"
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Figure 4.5 
Proliferation and collagen deposition of MEFs isolated from wildtype and CD248-/- mice 
(A) Proliferation studies. (B) Collagen deposition studies.   
A significant reduction in the proliferative capacity and the amount of collagen deposited by CD248-/- MEFs 
compared to wildtype MEFs was observed at baseline in unstimulated cells.  
In response to stimulation with PDGF-BB wildtype MEFs demonstrated a significant increase in proliferation 
relative to control. CD248-/- MEFs failed to proliferate following stimulation. In response to TGF!1 CD248-/- failed 
to deposit collagen but wildtype MEFs deposited large amounts of matrix. This trend in collagen deposition was 
also seen in response to stimulation with PDGF-BB but to a lesser extent. 
In response to TGF-!1 wildtype and CD248-/- MEFs both demonstrated a reduced proliferative response and a 
significant difference was seen between the two different cell groups (Two way ANOVA, n=3, *p=<0.05, 
**p<0.001, ***p=<0.0001 
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4.2.4 Isolation of renal cell populations from wildtype and CD248-/- mice 
To assess the function of CD248 in renal stromal cell populations, mesangial 
pericytes and tubulointerstitial fibroblasts were isolated from wildtype and knockout 
animals. Proximal tubular epithelial cells were isolated as a control. Isolation was 
achieved by infusing magnetic beads into the renal vasculature  (Figure 4.6). Beads 
were localised in the glomeruli, but not the tubulointerstitium, in tissue sections taken 
from the perfused kidney (Figure 4.6 A). Digestion of the kidney using collagenase 
and magnetic separation, split the kidney into glomerular and tubular fractions 
(Figure 4.6 B&C). Glomeruli were not seen in the tubular fraction. To assess yields 
following digestion, glomeruli were counted using a haemocytometer. No difference 
in the number of glomeruli isolated from wildtype and CD248-/- mice was seen (Figure 
4.6 D). To characterise the phenotype of the isolated cells, morphology and surface 
marker expression was assessed. Phase contrast microscopy of mesangial pericytes 
and interstitial fibroblasts demonstrated a mesenchymal cell pattern, in contrast to 
epithelial cells, which displayed a ‘cobble-stone’ morphology (Figure 4.8). No 
difference in the morphology of cells isolated from wildtype and knockout animals 
was observed. Assessment of cell surface markers using confocal microscopy 
demonstrated that all cells were negative for CD45 (leucocyte marker), CD31 
(endothelial marker) and synaptopodin (podocyte marker).  Mesangial pericytes and 
tubulointerstitial fibroblasts were positive for markers of mesenchyme (CD90, 
vimentin, fibronectin) but negative for the epithelial cell marker (Cytokeratin). 
Mesangial pericytes expressed desmin but tubulointerstitial fibroblasts did not. 
Proximal tubular epithelial cells expressed cytokeratin (Figure 4.9). 
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Figure 4.6 
Isolation of renal cell populations 
Isolation was achieved by infusing magnetic beads into the renal vasculature. 
(A) Beads were seen in haematoxylin and eosin stained tissue sections. x630 magnification.  
(B&C) Digestion of the kidney and magnetic separation split the kidney into glomerular (B) and (C) tubular 
fractions  
(D) To assess yields following digestion glomeruli were counted using a haemocytometer No difference in the 
number of glomeruli isolated from wildtype and CD248-/- mice was seen (student t-test, p>0.05, n=6). 
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Figure 4.7 
Morphology of isolated primary cell cultures 
Phase contrast microscopy of primary renal cells. x100 magnification. Mesangial pericytes and interstitial 
fibroblasts displayed a mesenchymal cell pattern. In contrast, epithelial cells displayed classical  ‘cobblestone’ 
morphology 
(A) Interstitial fibroblasts. (B) Mesangial pericytes. (C) proximal tubular epithelial cells. 
 
 
Figure 4.8 
Confocal microscopy to characterise renal cell populations 
 
(A) Mesangial cells 
 
(B) Tubulointerstitial fibroblasts 
 
(C) Proximal tubular epithelial cells 
 
All cells were negative for CD45 (leucocyte marker), CD31 (endothelial marker) and synaptopodin (podocyte 
marker).  Mesangial pericytes and tubulointerstitial fibroblasts were positive for markers of mesenchyme (CD90, 
vimentin, fibronectin) but negative for the epithelial cell marker (Cytokeratin). Mesangial pericytes expressed 
desmin but tubulointerstitial fibroblasts did not. Proximal tubular epithelial cells expressed cytokeratin. 
Magnification x400. 
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4.2.5 In vitro functional studies using specific renal cell populations 
To assess the function of CD248 in renal stromal cell populations the assays 
performed in section 4.2.3 on MEFs were repeated using mesangial pericytes, 
tubulointerstitial fibroblasts and proximal tubular epithelial cells isolated from wildtype 
and CD248-/- animals. 
 
Mesangial pericytes and tubulointerstitial fibroblasts from CD248-/- animals, but not 
proximal tubular epithelial cells demonstrated a baseline proliferative defect after 6 
days of culture (figure 4.9). In vitro CD248-/- stromal cells, but not epithelial cells 
demonstrated a deficiency in PDGF-BB mediated proliferation. In response to the 
mitogenic effects of PDGF-BB all cell populations proliferated, however, this 
response was significantly blunted in CD248-/- stromal cell populations but not in 
epithelial cells. Mesangial pericytes isolated from CD248-/- demonstrated a significant 
proliferative response to TGF-β1, in contrast this effect was not observed in 
tubulointerstitial fibroblasts or proximal tubular epithelial cells.  
 
To confirm the baseline defect in proliferation seen in the 96 well plate assays an in 
vitro wound healing assay was performed (figure 4.10). Again in response to injury 
CD248-/- stromal cells proliferated significantly slower than cells isolated from 
wildtype animals. No difference between wildtype and CD248-/- PTECs was seen in 
response to injury.  
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Figure 4.9 
Proliferation studies using renal cell populations 
 
In vitro CD248-/- mesangial pericytes and interstitial fibroblasts but not proximal tubular epithelial cells 
exhibit a deficiency in PDGF-BB mediated proliferation. (Two way ANOVA, n=3, *p=<0.05, **p<0.001, 
***p=<0.0001). 
 
(A-C) Mesangial cells and interstitial fibroblasts but not proximal tubular epithelial cells demonstrated a baseline 
proliferative defect (t test, n=3, *p<0.05, **p<0.01).  
 
(D-I) Day 6 proliferation data following growth factor treatment (PDGF-BB 100ng/ml TGF!1 10ng/ml) Mean+/-SEM 
expressed as percentage of control (vehicle alone). 
 
(D-F) In response to the mitogenic effects of PDGF-BB all cell populations proliferated, however, this response 
was significantly blunted in CD248-/- stromal cell populations but not in epithelial cells.  
 
(G-I) Mesangial cells isolated from CD248-/- demonstrated a significant proliferative response to TGF-!1 but this 
effect was not observed in fibroblasts or epithelial cells.  
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Figure 4.10 
Wound healing assay 
Cells were seeded into 6 well plates and cultured to confluence. Using a sterile 200 ml pipette tip a straight 
scratch was made in the confluent cell monolayer. Phase contrast images were captured from the plate at 0, 6, 12 
and 24 hours following monolayer injury.  
Image analysis was performed by marking the leading edge on the both sides of the wound using NIH imageJ; 
the distance was measured and expressed as a percentage of the wound area at time 0. In response to injury 
CD248-/- stromal cells proliferated slower than cells isolated from wildtype animals. No difference between 
wildtype and CD248-/- PTECs was seen in response to injury. (Two-way ANOVA with Bonferroni post-test relative 
to control, n=3 *p=<0.05). 
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The capacity for matrix deposition by CD248-/- renal cell populations was also 
assessed (figure 4.11).  As previously seen in CD248-/- MEFs, mesangial pericytes 
and tubulointerstitial fibroblasts isolated from CD248-/- mice had a baseline defect in 
collagen deposition in vitro. No defect in collagen deposition by epithelial cells 
isolated from wildtype or CD248-/- animals was observed.  
 
In response to stimulation by the growth factors PDGF-BB and TGFβ1, interstitial 
fibroblasts and PTEC deposited matrix. Interstitial fibroblasts deposited greater 
amounts of matrix than PTEC. Wildtype and CD248-/- isolated cells responded 
similarly. In contrast, mesangial pericytes isolated from CD248-/- animals responded 
differently to stimulation than wildtype cells. Wildtype mesangial pericytes increased 
matrix deposition in response to stimulation with PDGF and TGFβ1, however, 
CD248-/- mesangial pericytes significantly decreased collagen deposition in response 
to stimulation (figure 4.11) 
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Figure 4.11 
 
Collagen deposition studies using renal cell populations 
 
Mesangial pericytes (A) and tubulointerstitial fibroblasts (B) isolated from CD248-/- mice had a baseline defect in 
collagen deposition in vitro. No defect in collagen deposition by epithelial cells (C) isolated from wildtype or 
CD248-/- animals was observed.  
 
In response to growth factor stimulation interstitial fibroblasts and PTEC deposited matrix. Wildtype and CD248-/- 
isolated cells responded similarly. In contrast CD248-/- mesangial pericytes significantly decreased collagen 
deposition in response to stimulation (Two-way ANOVA, n=3, *p=<0.05, **p<0.001, ***p=<0.0001) 
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4.3 Discussion 
The expression of CD248 in murine kidney is poorly described and the renal 
architecture and function of CD248-/- mice has not previously been assessed in 
detail. In the studies described above the pattern of murine CD248 expression seen 
in wildtype mice mirrored the expression patterns identified in chapter 3 using human 
kidney tissue.  
 
As previously described at non-renal sites, expression was high during development 
and became downregulated in adult tissue. CD248+ cells were observed to represent 
mesangial pericytes of the glomerulus and also a population of peri-tubular stromal 
cells that were seen to associate with the interstitial vasculature. Histopathological 
examination demonstrated that CD248-/- mice had normal renal architecture with no 
gross glomerular or tubular abnormalities. An observation supported by no 
discernable biochemical difference between wildtype and CD248-/- renal function or 
urinary protein loss, which suggests glomerular and tubular structures are intact. 
 
These studies support and extend earlier morphological descriptions of murine 
CD248 expression in vivo. Macfadyen et al have previously identified weak 
expression in the murine glomerulus but failed to identify the interstitial population of 
CD248+ stromal cells seen in these present studies (158). This may be due to 
differences in CD248 expression between mouse strains. The studies reported by 
Macfadyen et al used the C57/BL6 background, not 129SvEV mice and strain 
differences are recognised (288), however, an identical population of cells was also 
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seen in the human tissue samples analysed. It is therefore more likely that the earlier 
studies failed to identify the interstitial population due to technical issues. The 
interstitial space is difficult to analyse using simple immersion fixation as the space 
and capillaries collapse and the tubules swell when histologically fixed without first 
perfusing the animals to support the renal architecture, thus small populations of cells 
can easily be missed (13).  Similarly high amounts of endogenous alkaline 
phosphatase in proximal tubular epithelial cells of the kidney can make it difficult to 
reduce non-specific immunostaining and a small population of cells in the interstitium 
could easily be missed.  
 
In the studies reported here a CD248+ interstitial population of cells was identified in 
human and murine tissue using immunoenzyme histochemistry and confocal 
microscopy, further all murine samples were perfused prior to fixation to preserve 
interstitial architecture. In contrast to the studies reported here, Huang et al (270) 
have recently reported CD248 to be expressed by podocytes and endothelial cells in 
the glomerulus in addition to mesangial cells. These studies used a CD248-LacZ 
knock-in mouse and an antibody against vimentin as a marker of podocytes. 
Vimentin is expressed on mesangial pericytes and this may confound these 
observations. Huang et al also used CD31 immunostaining to identify CD248+ 
endothelial cells; only 50% of endothelial cells were identified to express CD248. Low 
powered confocal microscopy images were used to quantify expression and this 
raises the possibility that the CD31+ staining is an artefact due to bleed through from 
adjacent LacZ+ mesangial pericytes. CD31 was not seen to co-localise with CD248 in 
the studies reported in this chapter and by others previously (158, 163, 253). 
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Histomorphological evaluation of haematoxylin and eosin stained and periodic acid 
silver stained tissue sections demonstrated no difference between wildtype and 
CD248-/- kidney structure. This is perhaps surprising given the profound renal and 
vascular abnormalities seen in PDGF-BB and PDGFRβ knock out mice. Both PDGF-
B and PDGFR−β deficient mice have defective formation of the glomerular 
mesangium, a phenotype that can be replicated postnatally in young animals using 
functional blocking antibodies (177, 178, 223). The functional role and importance of 
CD248 in renal development in vivo is therefore unclear, but the in vitro studies 
performed here do suggest that the constitutive removal of CD248 leads to a 
functional defect in renal stromal cells. 
 
Stromal cells (tubulointerstitial fibroblasts and mesangial pericytes) isolated from 
CD248-/- mouse kidneys had a significantly reduced baseline proliferative, wound 
healing and matrix depositing capacity compared to cells isolated from wildtype 
animals. A similar trend in proliferation was also seen using CD248-/- MEFS, and this 
recapitulates earlier studies reported by our group using a 5-hydroxytryptamine-3H 
uptake assay to measure proliferation (164).  
 
In response to the mitogenic effects of PDGF-BB all cell populations proliferated, 
however, this response was significantly blunted in CD248-/- stromal cell populations 
but not in epithelial cells. Mesangial cells isolated from CD248-/- demonstrated a 
significant proliferative response to TGF-β1 but this effect was not observed in 
fibroblasts or epithelial cells. Similarly wildtype mesangial pericytes increased matrix 
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deposition in response to stimulation with PDGF and TGFβ1, however, CD248-/- 
mesangial pericytes significantly downregulated collagen deposition in response to 
stimulation. This confirms earlier knock-in in vitro studies of CD248 function and 
suggests that CD248 signals in coordination with the PDGF receptor (166). In 
addition a role for TGF-β1 signalling and CD248 in mesangial pericytes but not 
fibroblasts is also suggested. However, the studies presented here require further 
confirmation and evaluation that was not possible during the time frame of this thesis. 
It is possible the functional defects observed are due to contamination of primary 
cultures by other renal cell types, although morphological and immunohistochemical 
assessment was used to characterise the cells used. The purity of these cultures 
could also be assessed using flow cytometry.  Similarly blocking antibody studies 
against PDGF-BB and TGF-β1 could be incorporated into the studies described here 
and protein analysis of downstream signalling molecules in the PDGF and TGFβ 
signalling pathways performed. 
 
In conclusion, in the resting kidney CD248 is found in the tubulointerstitium on 
vascular pericytes and fibroblasts, and in the glomerulus on mesangial pericytes. 
Resting CD248-/- animals have normal renal structure and function.  The functional 
defect observed in stromal cells following the constitutive removal of CD248 are 
suggestive that CD248-/- mice may be protected against the development of renal 
fibrosis following injury. Stromal cell proliferation and matrix deposition are key 
stages in disease progression. Furthermore pericyte proliferation and detachment 
from the vasculature is a source of myofibroblasts and vessel destabilisation and the 
removal of CD248 may ameliorate or reduce this process. 
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CHAPTER 5 
RENAL FIBROSIS IN CD248-/- MICE 
5.1 Introduction 
The description of the in vitro studies detailed in Chapter 4 suggest that renal stromal 
cell populations isolated from CD248-/- mice have an impaired functional response to 
pro-fibrotic growth factors. The human studies described in Chapter 3 have 
demonstrated that CD248 expression is increased in renal disease and expression is 
linked to the outcome of renal disease.   
 
It was not possible to identify any renal abnormalities in healthy adult CD248-/-  mice 
and therefore, in this chapter the function of CD248 in vivo in response to renal injury 
will be examined. Prior to the work described in this thesis our research group did not 
have an established model of murine renal fibrosis available to it. I will first describe 
two pilot studies of murine models of renal injury that were established in 
Birmingham. Following the development work undertaken in the pilot studies one of 
these models was then selected for use to induce renal injury in CD248-/- mice; and 
the disease phenotype in these animals was compared to that seen in wildtype 
animals of the same strain.  The degree of fibrosis and microvascular damage 
following injury was characterised and stromal and leucocyte populations assessed. 
The origin of CD248+ cells in this study was tracked using techniques that employed 
bone marrow chimeras.  
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It was established from this work that in response to renal injury CD248 expression is 
increased in the murine kidney and that CD248+ stromal cells are derived from 
resident renal cell populations. As previously described in human disease, CD248 
can be used to define subsets of stromal cells that are found in the injured kidney. 
CD248-/- mice were found to have fewer interstitial myofibroblasts following injury 
than wildtype animals, but no difference in leucocyte infiltration was observed. 
Crucially therefore, in response to renal injury CD248-/- mice are protected from the 
development of renal fibrosis and microvascular rarefaction. 
 
5.2 Small animal models of kidney disease 
Two established small animal models of renal injury were selected for use from the 
renal literature to be used in pilot studies to assess feasibility and outcome. The two 
models selected were the unilateral ureteric obstruction (UUO) model and the bovine 
serum albumin protein overload (BSAO) model.  
 
The UUO model was first developed in the early 1970s in rabbits where ligation of 
the ureter was shown to induce proliferation of αSMA positive myofibroblasts and 
increased interstitial deposition of collagen I, III and IV (289). The surgical technique 
has evolved and UUO is now most frequently performed in mice where it is safe, 
reproducible and well characterised. Within 24 hours complete UUO in mice initiates 
a rapid decline in renal blood flow and glomerular filtration rate. Following the 
procedure hydronephrosis develops and the interstitium is infiltrated by leukocytes. 
These infiltrating cells are predominately macrophages which secrete growth factors 
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and cytokines which act to induce an imbalance between tubular apoptosis and 
proliferation (290). Tubular epithelial cell death occurs with eventual progression to 
deposition of ECM and fibrosis and ultimately, after 7-14 days, loss of functioning 
renal parenchyma. The animals do not become uraemic as the contralateral kidney 
can maintain overall renal function.  
 
One limitation of the UUO model is that renal function and proteinuria cannot be 
measured, therefore, the second model piloted was the BSAO model first described 
by Eddy et al in the late 1980s using rats (291), this method was also later used to 
induce disease in mice (287). The serial intra-peritoneal administration of bovine 
serum albumin (BSA), over a period of weeks, leads to progressive irreversible 
fibrosis with marked leucocyte infiltration and stromal cell activation. Importantly the 
BSAO is able to model the signs of chronic disease, and the treated animals develop 
proteinuria, renal impairment and fibrosis. 
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5.3 Results 
5.3.1 Small animal models of renal fibrosis-pilot studies 
Two small pilot studies (n=3 per group) were performed to assess the UUO and 
BSAO models of renal fibrosis. For the UUO model a sham operated control group 
were used, in the BSAO model a control group received vehicle only intra-peritoneal 
injections on an identical schedule. Tissue histology and renal weight was assessed 
in all animals at the end of the pilot. In the BSAO model tissue was also 
immunostained to localise injected BSA in the kidney and urinary proteinuria was 
assessed. All animals tolerated the pilot studies with no adverse events. 
 
Serial injection of BSA failed to induce renal injury with no evidence of renal 
inflammation or fibrosis, small amounts of BSA were seen to localise to the 
glomerulus and proximal tubule in the treatment group but no significant increase in 
urinary protein loss could be detected (Figure 5.1). In contrast following UUO marked 
interstitial inflammation, tubular atrophy and renal fibrosis developed in the injured 
kidney. Renal mass, relative to body weight was also significantly reduced after 14 
days of injury (Figure 5.2). Sham operated animals were unaffected. After 
consideration and evaluation of the outcomes of the pilot studies, a decision was 
therefore made to use the UUO model for further experiments investigating the 
development of renal fibrosis in CD248-/- mice. 
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Figure  5.1  
Results of the BSAO pilot study 
(A) Kidney weight corrected for body weight. 
(B) Urinary protein loss and immunoenzyme histochemistry to localise BSA (brown) within the kidney. 
(C) Tissue histology 
(A &C) Serial injection of BSA failed to induce renal injury with no evidence of renal inflammation or fibrosis. (B) 
Small amounts of BSA were seen to localise to the glomerulus and proximal tubule in the treatment group but no 
significant increase in urinary protein loss could be detected. (Students t-test, p>0.05, n=3). 
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Figure 5.2 
Results of the UUO pilot study 
(A) Kidney weight corrected for body weight. 
(B) Tissue histology 
Following UUO marked interstitial inflammation, tubular atrophy and renal fibrosis developed in the injured kidney. 
Renal mass, relative to body weight was also significantly reduced after 14 days of injury (students t-test, 
p<0.001, n=3). 
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5.3.2 CD248 expression is upregulated following injury 
In human kidney disease CD248 expression in the interstitium increased with the 
development of interstitial fibrosis and damage; I therefore assessed if CD248 
expression in the murine kidney increased in response to the induction of renal injury 
using the UUO model. 
  
CD248 expression progressively increased in the tubulointerstitial compartment 
following renal injury compared to sham-operated control animals (Figure 5.3 A). The 
development of renal fibrosis correlated with a reduction in the kidney weight/body 
weight ratio (Figure 5.3 B) together with histological analysis that demonstrated an 
inflammatory infiltrate, tubular atrophy and interstitial expansion. Expression of 
CD248 mRNA in the injured kidney was significantly increased at 7 days post renal 
injury compared to sham operated control animals. This trend was maintained and 
increased at day 14 (Figure 5.3 C). Confirmation of CD248 protein expression was 
established by western blot analysis (Figure 5.3 D). 
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Figure 5.3 
   
CD248 expression is increased following UUO 
 
(Ai) In sham operated kidney tissue CD248 was expressed by mesangial pericytes of the glomerulus (arrow) and 
by peri-tubular stromal cells (**). (Aii) At 14 days following UUO tubular dilatation and interstitial expansion 
accompany increased CD248 (brown) expression in the interstitial space (arrows). Magnification x200. (B) Renal 
inflammation and fibrosis developed as CD248 expression increased as evidenced by an initial increase in the 
kidney weight/body weight ratio on day 3 after injury followed by a reduction by day 14 compared to sham 
operated animals. (C) Immunostaining of CD248 expression was confirmed by quantitative polymerase chain 
reaction on whole kidneys. Results are expressed as mRNA fold change mean +/- SEM relative to the control 
group (sham operated day 14) (one way ANOVA with bonferroni’s post test relative to control *p<0.01, **p<0.001, 
n=6). (D) Whole kidney lysates were also used to demonstrate CD248 protein expression at baseline (no 
operation performed), following a sham operation on day 14 and after UUO for 3, 7 and 14 days. 
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5.3.3  Stromal cell subpopulations following renal injury 
In chapter 3, human studies suggest that subpopulations of CD248 stromal cells exist 
in inflamed renal tissue therefore these populations were also assessed in mice 
following UUO.  
 
Duffield et al have recently suggested that all myofibroblasts are derived from 
PDGFRβ+ stromal cell populations (51). Previously it was not possible to assess the 
expression of this marker by stromal cells in the human studies performed due to 
technical limitations. The availability of frozen sections here from mice following UUO 
now made this analysis possible. Tissue from the mice stained for CD248, αSMA and 
PDGFRβ and was examined using confocal microscopy. Populations of single, 
double and triple positive stained cells were identified and counted at days 0, 3, 7 
and 14 following injury (Figure 5.4 and 5.5). 
 
A small population of CD248+ cells were seen in the interstitium prior to UUO. 
Glomeruli and blood vessels that stained positive for any of the three markers were 
excluded from the analysis. Following injury all stromal cell populations expanded in 
number and this was greatest at day 14 (Figure 5.5). As previously described in 
human disease, in chapter 3, CD248+αSMA+ myofibroblasts as well as a population 
of CD248+αSMA- cells were identified. These subpopulations could further be 
subdivided using the marker PDGFRβ. 
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Figure 5.4 
Stromal cell subpopulations following UUO day 14 
Tissue was stained for CD248 (blue), #SMA (red) and PDGFR! (green) and was examined using the confocal 
microscopy. Populations of single (A-C), double (D-F) and triple (G) positive stained cells were identified (arrows). 
Magnification x630. 
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Figure 5.5 
 
Cell counts of stromal cell subpopulations 
A small population of CD248+ cells were seen in the interstitium prior to injury (A).  
Populations of single (A-C), double (D-F) and triple positive (G) stained cells were identified and counted at days 
0, 3, 7 and 14 following injury.  Following injury all stromal cell populations expanded in number, and this was 
greatest at day 14. (One-way ANOVA with bonferroni’s post test relative to control *p<0.05, **p<0.01, ***p<0.001 
n=6) 
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5.3.4 Origin of CD248+ stromal cells in the UUO model. 
To identify the origin of CD248+ stromal cells in the tubulointerstitium in response to 
renal injury wildtype mice were injected with Bromodeoxyuridine (BrdU). BrdU was 
observed to be incorporated into proliferating CD248+ cells at 7 days following injury 
(Figure 5.6). BrdU was seen in the cytoplasm of some CD248+ cells suggesting that 
not all of the stromal cells were in S phase of the cell cycle.  
 
To exclude the possibility of a haemopoetic origin for CD248+ cell populations, bone 
marrow chimeras where yellow fluorescent protein (YFP) has been placed under the 
ubiquitin promoter of all bone marrow derived cells were generated. Renal injury was 
then performed. CD248 was expressed by resident stromal cells but not by infiltrating 
(donor) CD45+ bone marrow derived cells (Figure 5.7), which suggests that cells 
expressing CD248 in response to injury originate from the resident stromal cell 
population. 
Figure 5.6 
BrdU incorporation into CD248+ stromal cells 7 days following UUO 
BrdU (green) was seen to be incorporated into the nuclei (blue) of CD248+ (red) stromal cells following UUO, 
appears cyan (arrows). Some CD248+ cells were not in the S phase of cell cycle and consequently BrdU 
localised to the cytoplasm (n=3). Magnification x 630.  
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Figure 5.7 
CD248+ stromal cells are derived from resident cell populations 
 
Bone marrow chimera studies. Tissue from day 14 injured tissues is shown. Yellow fluorescent protein (YFP) 
(green) co-localises within infiltrating CD45+ leucocytes (red) but not within resident CD248+ stromal cells (blue). 
Magnification x400. (n=3) 
. 
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5.3.5 CD248-/- mice are protected against the development of renal 
fibrosis  
The impact of the constitutive removal of CD248 on the evolution of renal injury was 
assessed. It was established with the use of picosirius red staining that in response 
to renal injury CD248-/- mice deposited significantly less fibrillary collagen in the 
tubulointerstitial space by day 14 following the injury. The overall diminishment was 
measured to be 42% less when compared to wildtype controls (Figure 5.8A). 
Similarly, Collagen 1a mRNA transcription was significantly increased in wildtype 
animals following injury but this response was blunted in CD248-/- mice (Figure 5.8B). 
Interstitial collagen is deposited by myofibroblasts in response to injury. The number 
of myofibroblasts was, therefore quantified in wildtype and CD248-/- kidney tissue 
following injury (Figure 5.8D). CD248-/- animals had a significant reduction in the 
number of interstitial myofibroblasts compared to controls 14 days post UUO.  
 
Leucocyte infiltration was also assessed (Figure 5.9). No significant difference in 
infiltration by F4/80+ macrophages or CD3+ T cells was observed in wildtype and 
CD248-/- mice following injury (Figure 5.9 A and B). As previously observed using 
chimeric animals CD248 was not co-expressed on infiltrating CD45+ cells (Figure 
5.9C). 
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Figure 5.8 
 
Collagen deposition and myofibroblast accumulation 
 
In vivo CD248-/- mice accumulate less interstitial collagen and have fewer myofibroblasts than wildtype 
mice following unilateral ureteric obstruction  
 
(A) Picosirius red staining of sham operated and UUO day 14 kidney tissue. Magnification x400. 
 
(B) Confocal microscopy images of renal tissue stained for αSMA (red). Nuclei appear grey. Magnification x400  
 
(C) Digital quantification of picosirius red staining expressed as the percentage area of collagen per high power 
field (hpf). Collagen (red) expression is increased in wildtype and CD248-/- mice following injury. CD248-/- mice 
deposited significantly less collagen after 14 days of UUO (42% reduction, two way ANOVA, n=6, ***p<0.001, 
**p<0.01).  
 
(D) Collagen1a (col1a) RNA expression was measured by quantitative polymerase chain reaction on whole 
kidneys. Results are expressed as mRNA fold change mean +/- SEM relative to the control group (sham operated 
day 14). In wildtype animals’ col1a RNA expression was significantly increased at days 7 and 14 following injury. 
In CD248-/- mice col1a RNA expression was increased in response to injury but levels were blunted with no 
significant difference in col1a RNA expression at day 3, 7 and 14. Col1a RNA expression was significantly 
reduced in CD248-/- mice at day 14 following injury compared expression in wildtype mice (two way ANOVA, n=6, 
*p<0.05, **p<0.01).  
 
(E) CD248-/- mice had significantly fewer αSMA+ myofibroblasts at day 14 following UUO (student t-test, n=6,  
***p<0.001) 
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Figure 5.9 
Leucocyte infiltration following UUO 
No difference in leucocyte infiltration was observed in wildtype and CD248-/- mice following unilateral 
ureteric obstruction.  
 
(A) F4/80 was used as a marker of murine macrophages. (Ai) F4/80 (brown) expression was increased in the 
interstitium of wildtype and CD248-/- mice after 14 days UUO when compared to a sham operated day 14 control 
group. (Aii) F4/80 expression was confirmed by quantitative polymerase chain reaction on whole kidneys. Results 
are expressed as mRNA fold change mean +/- SEM relative to the control group (sham operated day 14). F4/80 
RNA expression in wildtype and CD248-/- was significantly increased following injury but no difference was 
observed in RNA expression between wildtype and CD248-/- tissue at day 14 (Two way ANOVA, n=6, *p=<0.05, 
***p=<0.0001).  
 
(B) CD3 was used as a marker of murine T lymphocytes. (Bi) CD3 (brown) expression was increased in the 
interstitium of wildtype and CD248-/- mice after 14 days UUO when compared to a sham operated day 14 control 
group. (Bii) CD3 RNA expression in wildtype and CD248-/- was significantly increased following injury but no 
difference was observed in RNA expression between wildtype and CD248-/- tissue at day 14.  
 
(C) Confocal microscopy x400 magnification. CD248 (Green) did not co-localise with the pan-leucocyte marker 
CD45 (red) in wildtype animals following 14 days UUO. 
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5.3.5 Microvascular rarefaction following injury 
Recent work has demonstrated that in response to renal injury pericytes migrate 
away from the capillary wall into the tubulointerstitium where they differentiate into 
collagen producing myofibroblasts contributing to fibrotic scar formation (95). The 
detachment and migration into the tubulointerstitium of pericytes leads to vascular 
de-stabilisation and ultimately vascular regression (95). These findings directed 
attention to the architecture of the renal vasculature in CD248-/- mice following injury. 
Blood vessel area was digitally quantified in wildtype and CD248-/- mice using the 
endothelial cell marker CD31.  Prior to injury no difference could be detected in 
vessel density between the wildtype and CD248-/- animals (Figure 5.10). Following 
injury there was an initial increase in vessel density at 3 days post injury followed by 
progressive vascular regression at 14 days post injury in wildtype animals. These 
findings were consistent with the vascular regression (microvascular rarefaction) 
reported by other groups in response to UUO injury (95). In contrast CD248-/- mice 
were protected from microvascular rarefaction in response to injury and no significant 
difference in CD31 area could be detected between sham operated animals and day 
14 injured animals in the CD248-/- group. In addition to assessing blood vessel area, 
vessel length was assessed as CD248 has previously been implicated in vessel 
maturation in response to injury (271). In wildtype animals following day 14 UUO 
there was evidence of defective vessel maturation and failure of the angiogeneic 
response to injury. We observed an increase in the number of small vessels 
(<100µm) but a significant reduction in larger vessels (>200µm) in wildtype animals. 
In CD248-/- animals this effect was not observed and the vessel lengths seen at day 
14 UUO were comparable to those observed in sham-operated animals. 
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Figure 5.10 
Vascular architecture in wildtype and CD248-/- following injury.  
 
Microvascular rarefaction is reduced in CD248-/- mice. CD31+ staining in day 14 sham operated or UUO 
kidney from wildtype (A and B ) and CD248-/- mice (C and D). Vessel length was assessed in resting (E) wildtype 
(F) and CD248-/- mice (G) following sham or UUO at day 14 (two way ANOVA, n=6, **p<0.01, ***p<0.001). Vessel 
density was assessed at various time points following UUO noted in resting (H) wildtype (I)  and CD248-/- mice (J) 
(one way ANOVA, n=6, *p<0.05 ***p<0.001). 
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5.4 Discussion 
Stromal fibrosis and microvascular rarefaction are reported in both human studies of 
renal disease and animal models, where they are considered pathomnemonic of 
progressive CKD (14, 94). In human studies both factors have consistently been 
reported to associate with a poorer disease outcome (31, 32, 42). Yet until relatively 
recently the mechanism for these histological associations has remained unclear.  
Furthermore, there has been significant debate within the literature regarding the 
origin of activated stromal cells in renal fibrosis with some authors favouring the 
expansion of resident renal cell populations and others suggesting the infiltration of 
bone marrow derived cell populations (92, 292). In chapter 3 and 4, I have previously 
demonstrated that CD248 is expressed on resident renal pericytes in non-inflamed 
tissue and in inflamed tissue CD248 is seen on αSMA+ myofibroblasts. Here my data 
shows that the increase in number of CD248+ cells seen in response to renal injury 
represents the expansion of a resident cell population.  
 
Careful tracking and kinetic modelling studies performed by Lin et al have 
demonstrated that in response to injury, collagen1α1+ pericytes upregulated classical 
pericyte markers (PDGFRβ, αSMA), upregulated collagen deposition and detached 
and migrated away from the underlying endothelium to form myofibroblasts. Later 
studies by the same group using the UUO model have demonstrated that this 
process is accompanied by microvascular rarefaction as loss of pericytes from the 
vasculature destabilises the vessel and leads to a failure of reparative angiogenesis 
(95). A phenotype confirmed here by my studies.  
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Chen et al have also demonstrated that in renal disease, PDGF receptor signalling is 
involved in pericyte activation, proliferation and differentiation into myofibroblasts(95, 
293).  The studies reported here mirror the renal phenotype described in the studies 
by the group of Duffield et al targeting PDGF signalling in vivo. These demonstrated 
that both exogenously administered tyrosine kinase inhibitors and endogenously 
generated soluble PDGFβ  receptor ectodomains were protective and stabilised the 
vasculature(95, 293). Furthermore, blockade of PDGF-BB signalling attenuated 
microvascular rarefaction and the development of renal fibrosis in vivo. CD248 is 
recognised to be pivotal in pericyte PDGF mediated proliferation (166) and my data 
in chapter 4 supports this hypothesis.  
 
CD248 is highly expressed in stromal cells found in inflamed tissue but is expressed 
at low levels in healthy tissue; consequently it is an appealing therapeutic target. 
Targeting single receptors restricted to pericytes is sufficient in some models to 
prevent fibrosis(95, 293). Pericyte detachment occurs early in the evolution of renal 
injury (51); therefore stabilising endothelial/pericyte crosstalk early to prevent 
proliferation, through the blockade of CD248 may be protective. Maia et al have 
demonstrated using a murine model of arthritis that CD248 contributes to synovial 
hyperplasia, fibrosis and leukocyte accumulation in inflammatory arthritis and that 
CD248 may represent a target for the treatment of arthritis (272). In contrast to these 
reports I did not detect a defect in leucocyte recruitment in the UUO model in CD248-
/- mice. CD248 may represent a target for treatment, with the advantage that it may 
allow modulation of PDGF signalling only on activated stromal cells found in inflamed 
tissue. 
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I propose that the constitutive removal of CD248 modulates the stromal renal 
pericyte functional response to the induction of injury. This serves to stabilise the 
vasculature and significantly reduces the formation of matrix depositing 
myofibroblasts. In conclusion, these studies provide further evidence that CD248 
expression is increased in response to renal injury by resident renal cell populations 
and advances our understanding of the functional role CD248 plays in the 
development of renal fibrosis, thus highlighting CD248 as a novel, stromal cell 
specific, therapeutic target.  
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 Introduction 
The nature of CKD causes it to impact significantly on the quality of life of sufferers 
and places high demands on the resources of our health care systems. CKD is a 
significant cause of premature morbidity and mortality. Dominant processes 
promoting progressive kidney disease, irrespective of the trigger, occur in the renal 
tubulointerstitial compartment where the deposition of non-functioning fibrotic matrix 
and microvascular rarefaction are considered hallmarks of progressive disease (5, 
94).   The stroma plays a key role in the maintenance of normal renal architecture 
and in the response to injury.  
 
This thesis examined the role of the novel stromal cell marker CD248 in human renal 
disease and demonstrates that the removal of CD248, at least in an animal model of 
renal disease, protects against the development of renal fibrosis. In human CKD, 
CD248 expression increased with disease severity; and expression was linked to 
known determinants of renal progression. Furthermore, CD248 expression levels can 
be used to triage patients into those categories that are at the greatest risk of 
progressing to ESRF.  In mice a resident population of stromal cells in the kidney 
expresses CD248. These cells are pericytes and fibroblasts. In response to injury in 
mice, as in humans, CD248 expression is increased. In vitro the loss of CD248 leads 
to defects in renal stromal cell function. In vivo CD248-/- mice are protected from 
renal fibrosis and microvascular rarefaction.  This phenotype is likely to be due to 
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stromal cell functional defects in response to growth factor signalling (Figure 6.1). 
Below the limitations of the current study are examined and discussed and areas for 
future work are considered. 
 
Figure 6.1  
 
Proposed role of CD248 in the pathogenesis of renal fibrosis 
 
(A) Normal kidney (B) Kidney injury in wildtype mice (C) Kidney injury in CD248-/- mice 
 
In the resting, healthy normal kidney, of wildtype and CD248-/- mice, pericytes are attached to the vasculature 
where they act to stabilise the endothelium. In response to renal injury (B), resident fibroblasts and pericytes 
become activated to form matrix-depositing myofibroblasts. Pericytes detach from the endothelium (arrow panel 
B), destabilising the vasculature causing the vessel to be lost (rarefaction). In CD248-/- mice this process is 
impaired, and consequently the vasculature is preserved (C) leading to a reduction in myofibroblast numbers and 
matrix deposition. Resident interstitial fibroblasts also have a reduced proliferative and matrix depositing capacity 
when CD248 is constitutively removed. 
 
 
 
 
6.2 Limitations and future areas for development 
IgA nephropathy has been used as a model of progressive human renal disease in 
this study. This is because IgA nephropathy has a more predictable clinical time 
course than many of the other renal diseases; patients are often younger with fewer 
co-morbidities that could potentially confound data analysis. Other investigators (140) 
have used this approach previously. CD248 expression was found to increase with 
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advancing disease, however, as this is only one cause of renal fibrosis this 
observation needs to be confirmed in a second cohort of patients with progressive 
renal disease. CD248 expression should also be investigated in non-proteinuric renal 
disease and in patients who have severely impaired non-progressive renal disease. 
Blood and urine analysis of CD248 expression could also be explored. Vessel 
coverage by pericytes using electron microscopy in human disease samples also 
needs to be performed given the results of the murine studies described here. 
 
In the human tissue samples a number of distinct stromal cell populations were 
found. These populations were also seen in the murine disease model used in 
chapter 5. Stromal cell heterogeneity is not a new idea. It has largely been ignored in 
the renal literature until recently (see chapter 1). The stromal cell subpopulations 
defined here by CD248 require further study. In situ tissue analysis presents 
difficulties and distinct subpopulations can be hard to describe, especially in inflamed 
stroma where cells are tightly clustered. Thus these cells need to be isolated and 
functionally characterised in vitro. A detailed understanding of the significance of 
individual subpopulations is crucial if novel stromal cell targeting therapies are to be 
developed against renal disease. Indeed, are these distinct cell subpopulations or are 
the markers used to define them simply markers of cell plasticity or proliferation? It is 
important to remember that the studies presented here do not remove the cells that 
express CD248 merely the protein; an important distinction if the results of this work 
are to be extrapolated to develop treatments for human disease.  One approach to 
isolate CD248+ stromal cell populations would be to develop transgenic animals 
where CD248 is linked to a Cre promoter.  These animals could then be bred to 
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reporter strains of mice that would tag all CD248+ cells. This would allow lineage 
tracing and fate mapping studies to be performed and also facilitate the isolation and 
identification of CD248+ subpopulations. The ultimate aim of these studies would be 
to modulate, enhance or delete distinct subpopulations of stroma in vivo to influence 
disease outcome. 
 
In Chapter 5 CD248-/- mice were protected against renal fibrosis and microvascular 
rarefaction following UUO. The results of the UUO model need be repeated in a 
second model of renal disease preferably in a different mouse strain to validate the 
observations reported here. It will also be important to know at which stage CD248+ 
stromal cell populations should be targeted for removal in disease models (early 
versus late disease) as all the studies presented here are in mice that have been 
born without CD248 and these animals may have adapted to its absence.  Therefore, 
functional blocking and deletion studies of CD248 in wildtype animals are required. 
Again CD248-Cre mice could be bred to place CD248 under the regulation of the 
diphtheria toxin receptor (DTR). This would then allow the temporal depletion of 
CD248 following the induction of renal injury. An alternative approach for 
consideration would be to inoculate animals with viral vectors capable of generating 
soluble CD248 ectodomains that block function in vivo. These studies would also 
need to be performed in models that allow the assessment of renal function and 
possibly death, as simply reducing interstitial collagen and preserving architecture in 
histological sections may not translate into improvements in disease outcomes and 
morbidities. The BSAO model piloted in chapter 5 would have allowed these studies 
to be performed but unfortunately, in my hands, this model failed to induce renal 
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fibrosis. This could be due to differences in animal strain, dosing schedule or local 
environmental factors, and further pilot studies are required to optimise this model for 
use in Birmingham. 
 
The in vivo findings shown in Chapter 5 suggest that the renal phenotype seen in 
CD248-/- mice, following UUO is due to the failure of pericytes to detach from the 
vasculature in response to injury. This hypothesis is supported by data recently 
published by Duffield et al. However, although I have been able show in vitro that 
loss of CD248 leads to defects in stromal cell function definitive evidence that this is 
the cause of the in vivo phenotype is lacking. Electron micrographs looking at the 
vasculature to assess pericyte coverage in wildtype and CD248-/- mice following 
injury may help to resolve this issue.  Alternatively, fate mapping of CD248+ cells 
using transgenic mice may help to address this issue further.  Additionally, co-culture 
vascular network forming assays using isolated CD248+ stromal cells and endothelial 
cells would allow CD248 function to be further dissected in vitro; and may be more 
physiologically relevant as it would allow an appreciation of the role CD248 plays in 
pericyte-endothelial cell crosstalk. 
 
In conclusion, this thesis characterises the role of the stromal cell protein CD248 in 
healthy and diseased human and murine kidney. A renal phenotype for CD248-/- mice 
in response to injury has been described and a potential mechanism for this 
phenotype has been identified. The identification of stromal subsets defined by 
CD248 in vivo is also an intriguing and novel observation.  Further work is required to 
extend the preliminary studies presented here. A greater appreciation of the role 
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CD248 plays in the evolution of fibrosis may facilitate the development of targeted 
stromal cell therapies that permit the deletion of activated stromal cell subsets to help 
prevent or ameliorate the development of CKD and ESRF. 
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